PharmGKB ID	Variant	Literature	Genes	Association	Significance	P-Value	# of Cases	# of Controls	Biogeographical Groups	Phenotype Categories	Pediatric	More Details	Molecules
982023304	rs3812718	PMID:22591328	SCN1A	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	yes	< 0.05	448		East Asian	Dosage	false	Patients with the TT genotype have increased maintenance dose and serum levels of carbamazepine between 3 and 12 months of treatment. No significant difference between genotypes was seen between 15 and 24 months of treatment. Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
1183629452	rs3219151	PMID:24061200	GABRA6	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.587	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184746653	rs2844665	PMCID:PMC3173287		Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	yes	= 2.69E-7	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
1184169619	rs3812718	PMID:24417206	SCN1A	Genotype CC is associated with increased cortical silent period duration due to carbamazepine in healthy individuals as compared to genotype TT.	yes	= 0.013	92		Unknown	Other	false	Paired-pulse transcranial magnetic stimulation was applied at baseline and after administration of either carbamazepine or placebo. In patients receiving carbamazepine, those with the GG genotype had a higher carbamazepine-induced increase in cortical silent period duration as compare to those with the AA genotype. Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
1183629441	rs2279020	PMID:24061200	GABRA1	Allele A is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	no	= 0.8361	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184469140	HLA-DRB1*07:01:01:01	PMID:24399721	HLA-DRB1	HLA-DRB1 *07:01:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	yes	= 0.003	20	125	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *07:01 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
1448266816	rs776746	PMID:26421491	CYP3A5	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	yes	= 0.006			East Asian	Metabolism/PK	false	The association with dose-adjusted carbamazepine concentration was signifiant when carbamazepine was taken in addition to phenytoin or phenobarbital.	carbamazepine
1183612568	rs2298771	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.81	2073		Multiple groups	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs.	carbamazepine; valproic acid
1184469132	HLA-DQB1*03:03:02:01	PMID:24399721	HLA-DQB1	HLA-DQB1 *03:03:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	yes	= 0.022	20	125	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *03:03 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
1184999606	rs3812718	PMID:25155934	SCN1A	Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	yes	< 0.001	207	246	East Asian	Efficacy	false	The TT genotype was more frequent in the drug resistant patients. The TC genotype was not found at a statistically higher frequency in patients with drug resistance.  Alleles have been complemented to the plus chromosomal strand. Variant described as SCN1A IVS5-91G>A. Remained significant after Bonferroni correction of p<0.041.	carbamazepine; oxcarbazepine
1451431060	HLA-B*15:02:01	PMID:33910375	HLA-B	HLA-B *15:02:01 is not associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	no	= 0.086	10	40	"Multiple groups, ""All included cases were pure Filipinos except for five patients (one case and four controls) who were considered as
mixed Filipinos. Those patients who were considered as mixed Filipinos had Chinese, German, Indian and Spanish
descent"" ""Mixed Filipino = at least one grandparent came from other race.""""Tagalog is the ethnolinguistic
group with the highest population in the Philippines. In this study, majority of the recruited patients belong
to this ethnolinguistic group suggesting that the study population is culturally almost homogenous. However,
the study population may not be representative of the Filipino population"""	Toxicity	false	"All of controls were people with epilepsy as were 8/10 cases the other cases were treated for mood stabilization and neuropathic pain. Authors stated that ""All of the tested alleles were not significantly associated with carbamazepine-induced SJS/TEN when the Bonferroni corrected p-value (<0.001) was used as reference."" but they also describe the HLA-B75 serotype, HLA-B*15:21 or HLA-A*24:07 alleles as significant. ""For HLA-B*15:02, there was no significant
difference in the prevalence of allele between the case and control groups"""	carbamazepine
1184469120	HLA-B*58:01	PMID:24399721	HLA-B	HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	yes	= 0.013	20	125	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *58:01 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
1183629461	rs211037	PMID:24061200	GABRG2	Allele C is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele T.	no	= 0.718	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
982023314	rs2298771	PMID:22591328	SCN1A	Genotype TT is associated with increased response to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	< 0.05	448		East Asian	Efficacy	false	"Patients with the TT genotype were more likely to have a ""good"" response to carbamazepine. A ""good"" response was classified as seizure free over 24 months of treatment. A ""bad"" response was classified as anything other than seizure free. This significant result was only seen for months 3-15 of treatment. No significant result was seen for months 15-24 months of treatment. Please note alleles have been complemented to the plus chromosomal strand."	carbamazepine
1184988858	HLA-B*15:02:01	PMID:22429379	HLA-B	HLA-B *15:02:01 is associated with Drug Hypersensitivity when treated with carbamazepine, oxcarbazepine, phenobarbital and phenytoin in women with Seizures.	not stated		2		East Asian	Toxicity	false	Case report with two female Han Chinese patients. The first patient developed maculopapular rash after receiving carbamazepine and then again after receiving oxcarbazepine. No rash occurred after treatment with levetiracetam. The second patient developed Stevens-Johnson Syndrome after receiving phenytoin, then developed a maculopapular eruption after receiving phenobarbital and then again after receiving carbamazepine. No reaction occurred after treatment with topiramate. The authors state that this study reports cross-reactivity to these anti-epileptics.	carbamazepine; oxcarbazepine; phenobarbital; phenytoin
1183629456	rs2229944	PMID:24061200	GABRB2	Allele G is not associated with differences in antiepileptic drugs resistance risk when treated with carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele A.	no	= 0.1233	441		Unknown	Efficacy	false	Association was investigated for antiepileptic drugs as a group.	carbamazepine; phenobarbital; phenytoin; valproic acid
1448821318	rs2298771	PMID:28753467	SCN1A	Allele C is associated with increased response to carbamazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, oxcarbazepine or valproic acid in children with Epilepsy as compared to allele T.	yes	= 0.013	216		European	Efficacy	true	All patients included in this study were receiving antiepileptic treatment as either mono or polytherapy.	carbamazepine; clobazam; ethosuximide; lamotrigine; levetiracetam; oxcarbazepine; valproic acid
1446902307	HLA-B*15:02:01	PMID:25647819	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	yes	= 3.51E-18	26	135	East Asian	Toxicity	false	Controls were patients tolerant to carbamazepine after taking it for at least 3 months without developing a skin rash.	carbamazepine
1184469126	HLA-C*03:02:01	PMID:24399721	HLA-C	HLA-C *03:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	yes	= 0.013	20	125	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *03:02 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
1183703727	rs2071197	PMID:24384557	HNF4A	Allele A is not associated with differences in carbamazepine disposition when treated with carbamazepine in people with Epilepsy as compared to allele G.	no		168		East Asian	Other	false		carbamazepine
1183703723	rs3814058	PMID:24384557	NR1I2	Allele C is not associated with differences in carbamazepine disposition when treated with carbamazepine in people with Epilepsy as compared to allele T.	no		168		East Asian	Other	false		carbamazepine
827823984	rs3812718	PMID:22188362	SCN1A	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	< 1.0E-4	234		East Asian	Dosage,Metabolism/PK	false	and decreased In concentration/dose ratio.	carbamazepine
1448265338	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMID:26223287	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with increased risk of Weight gain when treated with carbamazepine in women with Epilepsy as compared to CYP2C19 normal metabolizer genotype.	no	= 0.668	34	12	East Asian	Toxicity	false	Patients took carbamazepine for at least 6 months.	carbamazepine
827823998	rs3812718	PMID:22188362	SCN1A	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	yes	< 1.0E-4	234		East Asian	Dosage,Metabolism/PK	false	and decreased In concentration/dose ratio.	carbamazepine
1183703718	rs2276707	PMID:24384557	NR1I2	Allele T is not associated with differences in carbamazepine disposition when treated with carbamazepine in people with Epilepsy as compared to allele C.	no		168		East Asian	Other	false		carbamazepine
1183614112	rs17183814	PMID:23859570	SCN2A	Allele A is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.81	1430		"Multiple groups, 701 patients from Malaysia (Malay, Chinese or Indian), 803 patients from Hong Kong (Han Chinese). "	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction.	carbamazepine; valproic acid
994398056	HLA-B*15:02:01	PMCID:PMC3839910	HLA-B	HLA-B *15:02:01 is not associated with increased risk of Carbamazepine-induced hypersensitivity syndrome (HSS) when treated with carbamazepine in children.	no	= 1.0	42	91	Multiple groups	Toxicity	true		carbamazepine
1184469161	HLA-A*31:01:02	PMID:24322785	HLA-A	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	yes	< 0.001	10	8862	European	Toxicity	false	Patients with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) had a higher frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls or healthy population controls, in both European and Chinese populations.	carbamazepine
613976745	rs2234922	PMID:15692831	EPHX1	Allele G is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	yes	= 0.0351	96		East Asian	Dosage,Metabolism/PK	false	as part of a haplotype.	carbamazepine
1450376262	HLA-A*31:01:02	PMCID:PMC5798660	HLA-A	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema due to carbamazepine.	yes	= 1.47E-10	95	868	European	Toxicity	false	Association seen in patients of European ethnicity	carbamazepine
1183703735	rs2071197	PMID:24384557	HNF4A	Genotype GG is associated with increased concentration-to-dose ratios when treated with carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	yes	= 0.005	49		East Asian	Efficacy	false	Association was only found in carriers of the rs2276707 T/ rs3814058 C carriers compared to rs2276707 CC/ rs3814058 TT.	carbamazepine
1183703731	rs776746	PMID:24384557	CYP3A5	Allele C is not associated with differences in carbamazepine disposition when treated with carbamazepine in people with Epilepsy as compared to allele T.	no		168		East Asian	Other	false		carbamazepine
1184999651	rs3812718	PMID:25155934	SCN1A	Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	yes	= 0.002	170	156	East Asian	Efficacy	false	The TT genotype was more frequent in the drug resistant patients treated with carbamazepine/oxcarbamazepine monotherapy. The TC genotype was not found at a statistically higher frequency in patients with drug resistance. Alleles have been complemented to the plus chromosomal strand. Variant described as SCN1A IVS5-91G>A. Remained significant after Bonferroni correction of p<0.041.	carbamazepine; oxcarbazepine
1296599306	rs3740067	PMID:24567120	ABCC2	Genotypes CG + GG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype CC.	no	= 0.17	229		Unknown	Efficacy	false	The rs3740067 SNP did not affect time to first seizure or time to 12-month remission. Please note that this SNP was used as a surrogate marker for rs3740066 (linkage disequilibrium r2 = 1).	carbamazepine
1450822204	HLA-A*31:01:02	PMID:31066027	HLA-A	HLA-A *31:01:02 is associated with increased risk of drug-induced liver injury when treated with carbamazepine.	yes	= 0.0004	12	8438	European	Toxicity	false		carbamazepine
1450376244	HLA-B*15:02:01	PMCID:PMC5798660	HLA-B	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema due to carbamazepine.	no	= 0.53	23	187	East Asian	Toxicity	false		carbamazepine
1296599297	rs2273697	PMID:24567120	ABCC2	Genotypes AA + AG is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype GG.	no	= 0.647	134		Unknown	Efficacy	false	The rs2273697 SNP did not affect time to first seizure or time to 12-month remission.	carbamazepine
1296598788	HLA-B*51:01:01	PMID:22211527	HLA-B	HLA-B *51:01:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	yes	= 0.031	15	33	East Asian	Toxicity	false	Patients with carbamazepine-induced adverse drug reactions had a greater frequency of the HLA-B*51:01 allele as compared to carbamazepine-tolerant patients.	carbamazepine
1450822197	HLA-A*31:01:02	PMID:31066027	HLA-A	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 2.2e-9	43	10701	European	Toxicity	false		carbamazepine
1450376254	HLA-A*31:01:02	PMCID:PMC5798660	HLA-A	HLA-A *31:01:02 is not associated with risk of Maculopapular Exanthema due to carbamazepine.	no	= 0.81	23	166	East Asian	Toxicity	false	No association in patients of Han Chinese ethnicity	carbamazepine
1184469204	HLA-A*31:01:02	PMID:24322785	HLA-A	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	= 0.001	20	8862	European	Toxicity	false	Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant differences in *31:01 allele frequency were seen between patients with carbamazepine-induced SJS or TEN, and carbamazepine-tolerant patients or healthy population controls, either in a European or Chinese population.	carbamazepine
1184469192	HLA-B*15:02:01	PMID:24322785	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.001	53	710	East Asian	Toxicity	false	Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Chinese patients with carbamazepine-induced SJS or TEN had a higher frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls or healthy population controls. This result was NOT significant in a European population.	carbamazepine
1184755407	HLA-B*15:02:01	PMID:19018717	HLA-B	HLA-B *15:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	not stated	= 1.0E-4	18		East Asian	Toxicity	false	This allele was not observed in any of the patients.	carbamazepine; phenobarbital; phenytoin; zonisamide
981349421	HLA-B*40:01:01	PMID:16538176	HLA-B	HLA-B *40:01:01 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 2.6E-4	60	144	East Asian	Toxicity	false		carbamazepine
1447678493	rs1045642	PMCID:PMC4640545	ABCB1	Genotype GG is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	no	= 0.91	145		European	Efficacy	false	The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
1447678481	rs3812718	PMCID:PMC4640545	SCN1A	Genotype CC is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	no	= 0.97	145		European	Efficacy	false	The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
981349415	HLA-B*15:02:01	PMID:16538176	HLA-B	HLA-B *15:02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 1.6E-41	60	144	East Asian	Toxicity	false	The only CBZ-SJS patient who did not have the B*1502 allele, had instead, another HLA-B15 allele: HLA-B*1558.	carbamazepine
1447983639	HLA-B*15:02:01	PMID:23712814	HLA-B	HLA-B *15:02:01 is associated with risk of Stevens-Johnson Syndrome when treated with carbamazepine in women with Epilepsy.	not stated		1		Unknown	Toxicity	false	Case report. A 47-year-old woman of Asian decent. She had been on carbamazepine 300 mg twice daily for one month. HLA genetic testing revealed that the patient was HLA-B*15:02 positive. She was negative for HLA-A*31:01.	carbamazepine
981349408	HLA-B*15:02:01	PMID:16415921	HLA-B	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.	no		12		Multiple groups	Toxicity	false	Study looked at carbamazepine induced SJS in a European registry.  The 4 patients who were positive for HLA-B*1502 had Asian ancestry.	carbamazepine
1450822182	rs187926838	PMID:31066027	ALK	Allele G is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to allele A.	yes	= 4.9e-8	43	10701	European	Toxicity	false	This variant did not show an association with drug-induced liver injury (DILI), distinct from that seen with CBZ-SCAR.	carbamazepine
981349402	HLA-B*15:02:01	PMID:15057820	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	yes	= 3.13E-27	44	101	East Asian	Toxicity	false		carbamazepine
1184469245	HLA-B*15:02:01	PMID:24322785	HLA-B	HLA-B *15:02:01 is not associated with risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	no	= 0.001	10	8862	European	Toxicity	false	DRESS. No significant differences in *15:02 allele frequency were seen between patients with carbamazepine-induced DRESS, and carbamazepine-tolerant patients or healthy population controls, either in a European or Chinese population.	carbamazepine
1444707960	HLA-B*15:02:01	PMCID:PMC4415182	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.0001	38	25	East Asian	Toxicity	false	34/38 (89.5%) of those with severe cutaneous adverse reactions (Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), SJS/TEN overlap, drug reaction with eosinophilia and systemic symptoms (DRESS)) carried the *15:02 allele, as compared to 6/25 (24%) of controls. Carbamazepine prescribed for epilepsy, neuropathic pain, mental disorders, headache, muscular tics. The authors note that 3 patients had a history of prior rashes induced by phenytoin and phenobarbital in a total of 4 exposures.	carbamazepine
1448266807	rs15524	PMID:26421491	CYP3A5	Genotype AA is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.	yes	= 0.006			East Asian	Metabolism/PK	false	The association with dose-adjusted carbamazepine concentration was signifiant when carbamazepine was taken in addition to phenytoin or phenobarbital.	carbamazepine
613976830	rs3130690	PMID:16538176		Allele T is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele G.	yes	= 1.29E-39	60	144	East Asian	Toxicity	false		carbamazepine
992282434	HLA-A*31:01:02	PMCID:PMC3839910	HLA-A	HLA-A *31:01:02 is associated with increased risk of Carbamazepine-induced hypersensitivity syndrome when treated with carbamazepine in children.	yes	= 0.0025	42	91	Multiple groups	Toxicity	true		carbamazepine
1184746741	rs3130931	PMCID:PMC3173287	POU5F1	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	yes	= 7.78E-7	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
981954797	rs1128503	PMID:18812236	ABCB1	Allele A is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
981349397	HLA-B*15:02:01	PMID:18637831	HLA-B	HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine or phenytoin in people with Epilepsy.	no		21	50	East Asian	Toxicity	false		carbamazepine; phenytoin
1184469237	HLA-B*15:02:01	PMID:24322785	HLA-B	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	= 0.001	20	8862	European	Toxicity	false	Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). European patients with carbamazepine-induced SJS or TEN did not have a significantly different *15:02 allele frequency from carbamazepine-tolerant controls or healthy population controls. However, this result was significant in a Chinese population.	carbamazepine
613976821	rs2848716	PMID:16538176	MICA	Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele G.	yes	= 2.1E-14	60	144	East Asian	Toxicity	false		carbamazepine
1450822167	rs192543598	PMID:31066027		Allele G is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to allele A.	yes	= 1.7e-12	43	10701	European	Toxicity	false	This variant is in strong linkage disequilibrium (LD) with HLA-A*31:01.	carbamazepine
613976809	rs750332	PMID:16538176	BAG6; PRRC2A	Allele C is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine as compared to allele T.	yes	= 8.45E-12	60	144	East Asian	Toxicity	false		carbamazepine
981954805	rs2032582	PMID:18812236	ABCB1	Genotype AC is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
981349387	HLA-B*15:02:01	PMID:18637831	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	yes	= 5.0E-4	10	50	East Asian	Toxicity	false		carbamazepine
1444707947	HLA-B*15:02:01	PMCID:PMC4415182	HLA-B	HLA-B *15:02:01 is not associated with risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	no	= 0.159	3	25	East Asian	Toxicity	false	2/3 (66.7%) of those with drug reaction with eosinophilia and systemic symptoms (DRESS) carried the *15:02 allele, as compared to 6/25 (24%) of controls. Carbamazepine prescribed for epilepsy, neuropathic pain, mental disorders, headache, muscular tics.	carbamazepine
1184755431	HLA-B*07:02:01	PMID:19018717	HLA-B	HLA-B *07:02:01 is not associated with risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine, phenobarbital, phenytoin or zonisamide.	not stated	= 1.0E-4	18		East Asian	Toxicity	false	This allele was not observed in any of the patients.	carbamazepine; phenobarbital; phenytoin; zonisamide
1184746726	rs3815087	PMCID:PMC3173287	PSORS1C1	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele G.	yes	= 2.89E-27	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
994531642	HLA-B*15:02:01	PMCID:PMC3839910	HLA-B	HLA-B *15:02:01 is not associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.	no	= 1.0	42	91	Multiple groups	Toxicity	true		carbamazepine
1444707937	HLA-B*15:02:01	PMCID:PMC4415182	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	< 0.0001	35	25	East Asian	Toxicity	false	32/35 (91.4%) of those with Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS/TEN overlap carried the *15:02 allele, as compared to 6/25 (24%) of controls. Carbamazepine prescribed for epilepsy, neuropathic pain, mental disorders, headache, muscular tics.	carbamazepine
1447959759	HLA-B*15:02:01	PMID:27020614	HLA-B	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine in children with schizencephaly.	not stated		1		European	Toxicity	true	Case report. A 16-year-old Spanish Romani patient developed Stevens-Johnson syndrome upon treatment with carbamazepine. HLA typing showed the HLA-B*15:02 allele. A lymphocyte transformation test (LTT) gave positive results for carbamazepine, lamotrigine and phenytoin. The authors estimate an HLA-B*15:02 phenotype frequency of 2% in this ethnic group, and note that HLA-B testing might be useful in this population. The LTT results suggest cross reactivity between carbamazepine and other aromatic antiepileptic drugs.	carbamazepine
827824085	rs2032582	PMID:22188362	ABCB1	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1184467994	HLA-B*15:01:01:01	PMID:21917426	HLA-B	HLA-B *15:01:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (14.3%), HSS (23.5%) or SCARs (20.8%) and carbamazepine-tolerant controls (14%).	carbamazepine
827824080	rs1128503	PMID:22188362	ABCB1	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1447675598	rs3869066	PMID:26490229	ZNRD1-AS1	Genotypes AG + GG is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine as compared to genotype AA.	yes	= 0.0028	17	2873	East Asian	Toxicity	false	This SNP was in complete LD with HLA-A*31:01. Alleles complemented to positive strand compared to in Figure 1. Statistics were given for HLA-A*31:01 status.	carbamazepine
1184467987	HLA-A*33:03:01	PMID:21917426	HLA-A	HLA-A *33:03:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (14.2%), HSS (29.4%) or SCARs (25%) and carbamazepine-tolerant controls (24%).	carbamazepine
1444707987	HLA-B*46:01:01	PMCID:PMC4415182	HLA-B	HLA-B *46:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 0.03	38	25	East Asian	Toxicity	false	5/38 (13.2%) of those with severe cutaneous adverse reactions (Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), SJS/TEN overlap, drug reaction with eosinophilia and systemic symptoms (DRESS)) carried the *15:02 allele, as compared to 9/25 (36%) of controls.	carbamazepine
827824071	rs2234922	PMID:22188362	EPHX1	Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1448613065	rs2740574	PMID:28343093	CYP3A4	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1451306000	HLA-A*31:01:02	PMID:33356553	HLA-A	HLA-A *31:01:02 is not associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	no	= 0.8449	41	46		Toxicity	false		carbamazepine
1184467978	HLA-A*24:02:01:01	PMID:21917426	HLA-A	HLA-A *24:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (28.6%), HSS (17.6%) or SCARs (20.8%) and carbamazepine-tolerant controls (42%).	carbamazepine
1448613071	rs2687116	PMID:28343093	CYP3A4	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele A.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
769257794	rs1633021	PMID:21149285		Genotype TT is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine as compared to genotypes CC + CT.	yes	= 1.18E-13	55	898	East Asian	Toxicity	false	This SNP is in high LD with HLA-A*3101. Cases were patients who experienced severe cutaneous adverse reactions on carbamazepine, controls were healthy volunteers from the general population. p-value for significance was set at 1.12 x 10^-7 (0.05/444823).	carbamazepine
1448613059	rs3892097	PMID:28343093	CYP2D6	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1447678164	rs3812718	PMCID:PMC4640545	SCN1A	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	= 0.028	145		European	Metabolism/PK	false	The authors evaluated daily dose and maintenance dose and calculated the means for each genotype. The TT genotype is associated with a higher mean daily dose and higher mean maintenance dose of carbamazepine (CBZ). Mean CBZ daily dose (mg/day) for the TT genotype was 694 vs. 509-531 for the CT and CC genotypes, respectively. Mean CBZ maintenance dose for the TT genotype was 10.48 versus 7.79-7.96 for the CC and CT genotypes, respectively. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
981478948	rs3812718	PMID:21561445	SCN1A	Allele C is not associated with response to carbamazepine or oxcarbazepine in people with Epilepsy as compared to allele T.	no	= 0.686	204	311	European	Dosage,Efficacy	false	"""Case/Control"" numbers are for drug-responsive vs. drug-resistant patients.  More patients were taking carbamazepine than oxcarbazepine, and these groups were pooled for analysis."	carbamazepine; oxcarbazepine
1449004794	HLA-B*15:02:01	PMCID:PMC5753619	HLA-B	HLA-B *15:02:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.0021	12	236	East Asian	Toxicity	false	Allele frequency was higher in CBZ-induced SJS/TEN vs population controls and vs drug tolerant controls. This allele (along with others) is part of the HLA-B75 serotype, which was also significantly associated with SJS/TEN in this population.	carbamazepine
827824114	rs1045642	PMID:22188362	ABCB1	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1184468028	HLA-C*06:02:01:01	PMID:21917426	HLA-C	HLA-C *06:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (0.0%), HSS (23.5%) or SCARs (16.7%) and carbamazepine-tolerant controls (10%).	carbamazepine
1448635647	HLA-B*15:02:01	PMID:28570299	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 4E-08	80		East Asian	Toxicity	false	In Indians, the association was no longer significant after the conservative Bonferroni correction.	carbamazepine
981500456	rs3812718	PMID:22292851	SCN1A	Genotype TT is associated with increased risk of discontinuation when treated with carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	= 0.009	448		East Asian	Efficacy	false	Patients with the CC and CT genotypes had a higher retention rate than those with the TT genotype. The TT genotype was also a significant predictor of non-retention. Non-retention was defined as patients who ceased carbamazepine monotherapy before the end of the 12-month study period. Reasons for non-retention included allergies (n=15), central nervous system effects (n=55) and poor seizure control (n=106). Please note alleles have been complemented to the positive chromosomal strand.	carbamazepine
1184988681	HLA-B*15:02:01	PMID:24897291	HLA-B	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with carbamazepine.	no	= 0.17			East Asian	Toxicity	false	Meta-analysis with 4 studies. Cases were compared against drug-tolerant controls.	carbamazepine
1184407601	HLA-C*07:04:01	PMID:19694795	HLA-C	HLA-C *07:04:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	not stated		5	493	East Asian	Toxicity	false	Note that no p-value was given, only relative risk.	carbamazepine
1184469045	HLA-B*40:01:01	PMID:24268988	HLA-B	HLA-B *40:01:01 is not associated with risk of Drug Hypersensitivity when treated with carbamazepine.	no	> 0.05	74	152	East Asian	Toxicity	false	Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). No significant difference in the frequency of the *40:01 allele was seen between those with carbamazepine-induced MPE or DRESS and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.	carbamazepine
1184468020	HLA-C*03:04:01:01	PMID:21917426	HLA-C	HLA-C *03:04:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (0.0%), HSS (23.5%) or SCARs (16.7%) and carbamazepine-tolerant controls (12%).	carbamazepine
1184407607	HLA-B*15:02:01	PMID:19915237	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.0014	8	10	Central/South Asian	Toxicity	false	6 out of the 8 cases of carbamazepine-induced Stevens-Johnson Syndrome carried the *15:02 allele. None of the 10 normal controls carried the allele. The paper did not specify whether these were healthy population controls or carbamazepine-tolerant controls.	carbamazepine
1183702077	HLA-B*40:01:01	PMID:24336023	HLA-B	HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 1.08E-5	191	362	Multiple groups, Malaysian, Chinese, Korean, Thai, Indian, Japanese	Toxicity	false	HLA-B*4001 was observed to be protective, with a significant over-representation in CBZ-tolerant patients. cADR:Stevens-Johnson syndrome and toxic epidermal necrolysis (bullous lesions); hypersensitivity syndrome/maculopapular exanthema (nonbullous lesions)	carbamazepine
1184468008	HLA-C*01:02:01	PMID:21917426	HLA-C	HLA-C *01:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (17.6%) or SCARs (25%) and carbamazepine-tolerant controls (26%).	carbamazepine
1184407594	HLA-B*59:01:01:01	PMID:19694795	HLA-B	HLA-B *59:01:01:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	not stated		5	493	East Asian	Toxicity	false	Note that no p-value was given, only relative risk.	carbamazepine
1451430960	HLA-A*24:07	PMID:33910375	HLA-A	HLA-A *24:07 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	no	= 0.033	10	40	"Multiple groups, ""All included cases were pure Filipinos except for five patients (one case and four controls) who were considered as
mixed Filipinos. Those patients who were considered as mixed Filipinos had Chinese, German, Indian and Spanish
descent"" ""Mixed Filipino = at least one grandparent came from other race.""""Tagalog is the ethnolinguistic
group with the highest population in the Philippines. In this study, majority of the recruited patients belong
to this ethnolinguistic group suggesting that the study population is culturally almost homogenous. However,
the study population may not be representative of the Filipino population"""	Toxicity	false	"All of controls were people with epilepsy as were 8/10 cases the other cases were treated for mood stabilization and neuropathic pain. Authors stated that ""All of the tested alleles were not significantly associated with carbamazepine-induced SJS/TEN when the Bonferroni corrected p-value (<0.001) was used as reference."" but they also describe the HLA-B75 serotype, HLA-B*15:21 or HLA-A*24:07 alleles as significant."	carbamazepine
827824096	rs2032582	PMID:22188362	ABCB1	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1184468014	HLA-C*03:03:01	PMID:21917426	HLA-C	HLA-C *03:03:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (23.5%) or SCARs (29.1%) and carbamazepine-tolerant controls (24%).	carbamazepine
1184469038	HLA-B*51:01:01	PMID:24268988	HLA-B	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	112	152	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant difference in the frequency of the *51:01 allele was seen between those with carbamazepine-induced SJS or TEN and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.	carbamazepine
981500472	rs3812718	PMID:22292851	SCN1A	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	yes	= 0.021	272		East Asian	Dosage	false	Only patients who completed the full 12 months of carbamazepine therapy (i.e. the retention cohort) were included. Patients with the TT genotype had a higher maintenance dose and higher serum levels compared to those with the GG genotype. Please note alleles have been complemented to the positive chromosomal strand.	carbamazepine
1184988697	HLA-A*31:01:02	PMID:24897291	HLA-A	HLA-A *31:01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	< 0.0001			Multiple groups, Japanese, Caucasian, Korean	Toxicity	false	Meta-analysis, number of studies included was not given.	carbamazepine
1183702071	HLA-B*15:02:01	PMID:24336023	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 1.44E-12	336	692	Multiple groups, Malaysian, Chinese, Korean, Thai, Indian, Japanese	Toxicity	false	cADR:Stevens-Johnson syndrome and toxic epidermal necrolysis (bullous lesions); hypersensitivity syndrome/maculopapular exanthema (nonbullous lesions)	carbamazepine
1184412194	HLA-B*15:02:01	PMID:20345939	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 2.89E-12	42	42	East Asian	Toxicity	false	Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS; n=35) and toxic epidermal necrolysis (TEN; n=7). 37 of the 42 patients with SJS or TEN carried the *15:02 allele, compared to 5 of the 42 carbamazepine-tolerant controls.	carbamazepine
1184469027	HLA-B*51:01:01	PMID:24268988	HLA-B	HLA-B *51:01:01 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	yes	= 0.01	74	152	East Asian	Toxicity	false	Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). Patients with carbamazepine-induced MPE or MPE/DRESS had an increased frequency of the *51:01 allele, as compared to carbamazepine-tolerant controls. However, no significant difference in frequencies was seen when considering patients with DRESS alone. Adjusted p-values using Bonferroni's correction.	carbamazepine
1184407587	HLA-B*15:18:01	PMID:19694795	HLA-B	HLA-B *15:18:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	not stated		5	493	East Asian	Toxicity	false	Note that no p-value was given, only relative risk.	carbamazepine
1184468002	HLA-B*51:01:01	PMID:21917426	HLA-B	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (23.5%) or SCARs (29.1%) and carbamazepine-tolerant controls (20%).	carbamazepine
1183702064	HLA-A*31:01:02	PMID:24336023	HLA-A	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 4.28E-27	413	1020	Multiple groups, Asian and White	Toxicity	false	cADR:Stevens-Johnson syndrome and toxic epidermal necrolysis (bullous lesions); hypersensitivity syndrome/maculopapular exanthema (nonbullous lesions)	carbamazepine
1450968771	HLA-A*02:01	PMCID:PMC6989248	HLA-A	HLA-A *02:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or valproic acid in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	"This allele was present in 3 of 5 cases alongside other HLA alleles. Case 1: HLA-A*02:01/*26:01, HLA-B*15:11/*51:01, HLA-C*03:04/*15:02; Case 3 : HLA-A*02:01/*02:01, HLA-B*35:01/*51:01, HLA-C*03:04/*14:02; Case 4 : HLA-A*02:01/*02:10, HLA-B*15:11/*40:06, HLA-C*03:04/*08:01. Authors state ""Korean allele frequencies of the five cases' common alleles were 17.62% for -A*02:01""."	carbamazepine; valproic acid
1183702093	HLA-B*15:11:01	PMID:24336023	HLA-B	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	yes	= 1.1E-3	10	83	Multiple groups, Malaysian, Chinese, Korean, Thai, Indian, Japanese	Toxicity	false	Increased risk of carbamazepine (CBZ)-induced Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions. Meta-analysis on the basis of bullous cADRs; over-representation of HLA-B*1511 in patients showing bullous cADRs.	carbamazepine
1184469086	HLA-B*15:02:01	PMID:24394201	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 6.9E-8	13	26	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
1183702087	HLA-B*15:02:01	PMID:24336023	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	yes	= 1.88E-51	205	692	Multiple groups, Malaysian, Chinese, Korean, Thai, Indian, Japanese	Toxicity	false	Increased risk for carbamazepine (CBZ)-induced Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions. Meta-analysis on the basis of bullous cADRs	carbamazepine
1184468051	HLA-B*15:02:01	PMID:22053601	HLA-B	HLA-B *15:02:01 is not associated with risk of Exanthema when treated with carbamazepine in people with Epilepsy.	no	= 0.1032	11	8	East Asian	Toxicity	false	36.4% of the patients with a carbamazepine-induced rash carried the *15:02 allele, as compared to none of the carbamazepine-tolerant controls (however, note that two of the tolerant controls were listed only as having HLA-B*15).	carbamazepine
827824027	rs1051740	PMID:22188362	EPHX1	Genotype CC is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	yes	< 1.0E-4	234		East Asian	Dosage,Metabolism/PK	false	and decreased In concentration/dose ratio.	carbamazepine
827815322	rs2234922	PMID:19620853	EPHX1	Allele G is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	yes	= 0.027	70		Unknown	Dosage,Metabolism/PK	false	as part of a predictive algorithm that includes rs1051740, rs2234922 and age.	carbamazepine
981239981	rs1051740	PMID:15692831	EPHX1	Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele T.	yes	= 0.0241	58		East Asian	Dosage,Metabolism/PK	false		carbamazepine
993813998	HLA-A*31:01:02	PMCID:PMC3839910	HLA-A	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine in children.	yes	= 0.0037	42	91	Multiple groups	Toxicity	true		carbamazepine
1184468042	HLA-B*15:02:01	PMID:22053601	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	yes	= 0.0003	6	8	East Asian	Toxicity	false	100% of patients with Stevens-Johnson Syndrome carried the *15:02 allele, as compared to none of the carbamazepine-tolerant controls (however, note that two of the tolerant controls were listed only as having HLA-B*15).	carbamazepine
1448265345	CYP2C19 poor metabolizer and intermediate metabolizer genotypes	PMID:26223287	CYP2C19	CYP2C19 poor metabolizer and intermediate metabolizer genotypes is not associated with increased risk of Weight gain when treated with carbamazepine in men with Epilepsy as compared to CYP2C19 normal metabolizer genotype.	no	= 0.300	33	14	East Asian	Toxicity	false	Patients took carbamazepine for at least 6 months.	carbamazepine
1184469071	HLA-B*15:02:01	PMID:24496695	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine, oxcarbazepine and phenobarbital in children with Epilepsy.	yes	= 0.043	6	32	East Asian	Toxicity	true	Children with aromatic antiepileptic-induced Stevens-Johnson Syndrome had a higher frequency of the *15:02 allele, as compared to antiepileptic-tolerant controls and healthy population controls.	carbamazepine; oxcarbazepine; phenobarbital
827815311	rs1051740	PMID:19620853	EPHX1	Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.	yes	= 0.019	70		Unknown	Dosage,Metabolism/PK	false	as part of a predictive algorithm that includes rs1051740, rs2234922 and age.	carbamazepine
1183702102	HLA-A*24:02:01:01	PMID:24336023	HLA-A	HLA-A *24:02:01:01 is associated with decreased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis-bullous lesions when treated with carbamazepine.	yes	= 2.7E-3	67	194	Multiple groups, Malaysian, Chinese, Korean, Thai, Indian, Japanese	Toxicity	false	meta-analysis on the basis of bullous cADRs; Meta-analysis found a significant association of HLA-A*2402 as a protective factor in patients showing only bullous cADRs.	carbamazepine
1184468034	HLA-C*14:02:01	PMID:21917426	HLA-C	HLA-C *14:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (17.6%) or SCARs (25%) and carbamazepine-tolerant controls (16%).	carbamazepine
1184469112	HLA-A*33:03:01	PMID:24399721	HLA-A	HLA-A *33:03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	yes	= 0.000	20	125	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *33:03 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
827824050	rs2298771	PMID:22188362	SCN1A	Allele C is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1448613053	rs9332120	PMID:28343093	CYP2C9	Allele C is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele T.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1183606890	rs3812718	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.39	2475		Multiple groups	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs.	carbamazepine; valproic acid
1184469104	HLA-B*15:02:01	PMID:24399721	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with Epilepsy.	yes	= 0.000	35	125	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
827824060	rs17183814	PMID:22188362	SCN2A	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1448613046	rs1065852	PMID:28343093	CYP2D6	Allele A is associated with increased response to carbamazepine, lamotrigine, phenytoin, primidone or valproic acid in children with Epilepsy as compared to allele G.	yes		23	7	Unknown	Efficacy	true		carbamazepine; lamotrigine; phenytoin; primidone; valproic acid
1451431020	HLA-B*15:21	PMID:33910375	HLA-B	HLA-B *15:21 is associated with increased likelihood of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	no	= 0.046	10	40	"Multiple groups, ""All included cases were pure Filipinos except for five patients (one case and four controls) who were considered as
mixed Filipinos. Those patients who were considered as mixed Filipinos had Chinese, German, Indian and Spanish
descent"" ""Mixed Filipino = at least one grandparent came from other race.""""Tagalog is the ethnolinguistic
group with the highest population in the Philippines. In this study, majority of the recruited patients belong
to this ethnolinguistic group suggesting that the study population is culturally almost homogenous. However,
the study population may not be representative of the Filipino population"""	Toxicity	false	"All of controls were people with epilepsy as were 8/10 cases the other cases were treated for mood stabilization and neuropathic pain. Authors stated that ""All of the tested alleles were not significantly associated with carbamazepine-induced SJS/TEN
when the Bonferroni corrected p-value (<0.001) was used as reference."" but they also describe the HLA-B75 serotype, HLA-B*15:21 or HLA-A*24:07 alleles as significant."	carbamazepine
827824037	rs1051740	PMID:22188362	EPHX1	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.	yes	< 1.0E-4	234		East Asian	Dosage,Metabolism/PK	false	and decreased In concentration/dose ratio.	carbamazepine
982023290	rs2290732	PMID:22591328	GABRA1	Genotypes AA + AG are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.001	448		East Asian	Efficacy	false	Patients with the AA and AG genotypes have increased tolerability to carbamazepine. Tolerability was assessed by retention rates, or the proportion of patients that continued to take carbamazepine for seizures over the previous 3 months. Patients were assessed every 3 months for 24 months. The retention rates for the AA + AG genotypes were significantly greater than the retention rate for the GG genotype during months 9 - 24 of treatment.	carbamazepine
1449147028	HLA-B*15:02:01	PMID:29076187	HLA-B	HLA-B *15:02:01 is associated with Stevens-Johnson Syndrome when treated with carbamazepine.	not stated		12	11	Central/South Asian	Toxicity	false	A case-control study was undertaken on 12 patients who developed Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) after taking either phenytoin (n=8) or carbamazepine (n=4), and 11 tolerant controls. Only one patient had HLA-B*15:02 among the cases and controls; this patient developed SJS after receiving carbamazepine.	carbamazepine
981482101	HLA-B*15:02:01	PMID:23132554	HLA-B	HLA-B *15:02:01 is associated with increased risk of carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when treated with carbamazepine.	yes	< 1.0E-5	690	1585	East Asian	Toxicity	false		carbamazepine
982023280	rs3812718	PMID:22591328	SCN1A	Genotypes CC + CT are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype TT.	yes	= 0.038	448		East Asian	Efficacy	false	Patients with the CC and CT genotypes have increased tolerability to carbamazepine. Tolerability was assessed by retention rates, or the proportion of patients that continued to take carbamazepine for seizures over the preceding 3 months. Patients were assessed every 3 months for 24 months. The retention rates for the CC + CT genotypes were significantly greater than the retention rate for the TT genotype during months 9 - 15 of treatment. Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
981482109	HLA-A*31:01:02	PMID:23132554	HLA-A	HLA-A *31:01:02 is associated with increased risk of carbamazepine-induced hypersensitivity when treated with carbamazepine.	yes	< 1.0E-5	264	871	Multiple groups	Toxicity	false	HLA-A*3101 is significantly associated with all phenotypes of CBZ hypersensitivity in multiple ethnicities.	carbamazepine
981859205	rs2298771	PMCID:PMC3125053	SCN1A	Allele C is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no	= 0.91	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1184468379	HLA-B*15:02:01	PMID:24225276	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in children.	yes		5	10	Multiple groups, Singapore: Chinese, Malay, Indian	Toxicity	true	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Children who developed carbamazepine-induced SJS or TEN had an increased frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls.	carbamazepine
1185003427	HLA-B*15:02:01	PMID:25305458	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.035	9	37	Central/South Asian	Toxicity	false	The frequency of the *15:02 allele was higher in those with carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to carbamazepine-tolerant patients.	carbamazepine
1184999842	rs17183814	PMID:25155934	SCN2A	Genotype AA is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	no	= 0.139	207	246	East Asian	Efficacy	false	Genotypes of this SNP did not have significantly different frequencies in the drug resistant patients compared to drug responsive patients. Variant described as SCN2A c.56G>A.	carbamazepine; oxcarbazepine
1447980873	rs762551	PMID:26762380	CYP1A2	Genotype AA is associated with increased clearance of carbamazepine in children with Epilepsy as compared to genotypes AC + CC.	yes	= 0.0004	40		European	Metabolism/PK	true	The correlation between weight-adjusted carbamazepine dose and carbamazepine concentration after dose adjustment (r = 0.68, p = 0.0004). The equation that described population clearance (CL) was CL (l/h) = 0.176 + 0.0484 * SEX + 0.019 * CYP1A2+0.000156 * DD, (SEX has a value of 1 if male and 0 if female, CYP1A2 has a value of 1 if  AA and 0 if CC or AC, and DD is the total carbamazepine daily dose (mg/day).)	carbamazepine
981501834	rs3740066	PMCID:PMC3570048	ABCC2	Genotypes CT + TT are associated with decreased metabolism of carbamazepine in men with Epilepsy as compared to genotype CC.	yes	= 0.008	48		Multiple groups, African American and Caucasian.	Metabolism/PK	false	as measured by a lower carbamazepine-10-11 epoxide:carbamazepine metabolite ratio. This association was only significant in male patients.	carbamazepine
1184999851	rs2304016	PMID:25155934	SCN2A	Genotype GG is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype AA.	no	= 0.714	207	246	East Asian	Efficacy	false	Genotypes of this SNP did not have significantly different frequencies in the drug resistant patients compared to drug responsive patients. Alleles have been complemented to the plus chromosomal strand. Variant described as SCN2A IVS7-32A>G.	carbamazepine; oxcarbazepine
1184407446	HLA-B*08:01:01; HLA-B*40:01:01	PMID:16981842	HLA-B	HLA-B *40:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	no	= 0.1229	20	43	European	Toxicity	false	No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *40:01 allele, as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
1184999857	rs3740066	PMID:25155934	ABCC2	Genotype TT is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC.	no	= 0.819	207	246	East Asian	Efficacy	false	Genotypes of this SNP did not have significantly different frequencies in the drug resistant patients compared to drug responsive patients. Variant described as ABCC2 c.3972C>T.	carbamazepine; oxcarbazepine
981501842	rs4148386	PMCID:PMC3570048	ABCC2	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.012	30		African American/Afro-Caribbean	Metabolism/PK	false	This association was only significant in the African American patients and not in Caucasian patients. Carbamazepine-10-11 epoxide: carbamazepine ratio was also significantly higher in African American patients with AA+AG vs GG (p=0.049).	carbamazepine
1184746894	rs9469003	PMCID:PMC3173287	CYCSP5	Allele C is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele T.	yes	= 1.60E-9	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
769146060	rs2606345	PMID:21121773	CYP1A1	Allele A is associated with increased risk of Seizures when treated with carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.00297	101		Central/South Asian	Efficacy,Metabolism/PK	false	This association was found in women but not in men.  The authors postulate that this is modulated through metabolism of estradiol.	carbamazepine; phenobarbital; phenytoin; valproic acid
827824194	rs2273697	PMID:22188362	ABCC2	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1184407437	HLA-B*08:01:01; HLA-B*57:01:01	PMID:16981842	HLA-B	HLA-B *57:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	no	= 0.8936	20	79	European	Toxicity	false	No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *57:01 allele, as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
981859218	rs2279020	PMCID:PMC3125053	GABRA1	Genotype GG is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to genotype AA.	yes	= 0.031	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1184407424	HLA-B*08:01:01; HLA-B*44:02:01:01	PMID:16981842	HLA-B	HLA-B *44:02:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	no	= 0.27	20	79	European	Toxicity	false	No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *44:02 allele, as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
827824206	rs717620	PMID:22188362	ABCC2	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1183680916	HLA-B*40:01:01	PMID:23692434	HLA-B	HLA-B *40:01:01 is associated with decreased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	yes	= 0.004	26	135	East Asian	Toxicity	false	Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*40:01 allele have a decreased risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 26 cases were compared against 135 controls; cases developed SJS/TEN on carbamazepine, controls did not.	carbamazepine
1447678288	rs1051740	PMCID:PMC4640545	EPHX1	Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	yes	< 0.05	145		European	Metabolism/PK	false	The authors evaluated maintenance dose-adjusted concentrations of carbamazepine (CBZ), its active metabolite, CBZ-epoxide (CBZE), and its inactive metabolite CBZ-diol (CBZD) as well as CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios.The CC genotype is associated with a lower mean dose adj. concentration  of carbamazepine (CBZ) (microgram/mL per mg/Kg) (0.76 for the CC genotype vs. 0.94 &1.02 for the TT and CT genotypes, respectively). The C allele was also associated with a lower mean CBZ-diol to CBZ ratio (0.31 for TT vs. 0.23 & 0.25 for the CT & CC genotypes, respectively).	carbamazepine
981501851	rs7643645	PMCID:PMC3570048	NR1I2	Allele G is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	yes	= 0.04	88		Multiple groups, African Americans and Caucasians	Metabolism/PK	false	This association was significant in the whole cohort. As measured by a higher carbamazepine-10-11 epoxide: carbamazepine ratio.	carbamazepine
769257721	rs2032582	PMID:16753003	ABCB1	Allele C is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.	no		174		East Asian	Metabolism/PK,Other	false	as measured by steady-state CBZ concentration to the dose (C/D) ratios.	carbamazepine
613977017	rs506770	PMID:16538175	HSPA1A	Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele C.	yes	= 0.035	22	44	European	Toxicity	false	Allele G was considered protective against severe hypersensitivity.	carbamazepine
1184468408	HLA-B*15:02:01	PMID:24225276	HLA-B	HLA-B *15:02:01 is not associated with risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine in children.	no		6	10	Multiple groups, Singapore: Chinese, Malay, Indian	Toxicity	true	Hypersensitive skin syndrome (HSS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS). No significant difference in the frequency of the *15:02 allele was seen between children with carbamazepine-induced HSS and carbamazepine-tolerant controls.	carbamazepine
1448525687	HLA-B*15:02:01	PMID:27888155	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	< 0.001	2	253	European	Toxicity	false	"The frequency of the HLA-B*15:02 allele was significantly higher in cases of carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to a group of patients tolerant to carbamazepine, as well as a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""), and general population controls."	carbamazepine
769257724	rs1045642	PMID:16753003	ABCB1	Allele A is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to allele G.	no		126	84	East Asian	Efficacy	false	Not significant after Bonferonni correction.	antiepileptics; carbamazepine
981859232	rs2279020	PMCID:PMC3125053	GABRA1	Allele G is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	yes	= 0.02	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
769257727	rs2032582	PMID:16753003	ABCB1	Genotype AA is associated with increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to genotype CC.	no		126	84	East Asian	Efficacy	false	Not significant after Bonferonni correction.	antiepileptics; carbamazepine
981501862	rs2461817	PMCID:PMC3570048	NR1I2	Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A.	yes	= 0.006	88		Multiple groups, African Americans and Caucasians	Metabolism/PK	false	This association was significant in the whole cohort. As measured by a higher carbamazepine-10-11 epoxide: carbamazepine ratio. However, Allele C was associated with decreased clearance in African American patients (p=0.03, n=30).	carbamazepine
1184468415	HLA-B*15:02:01	PMID:24225276	HLA-B	HLA-B *15:02:01 is not associated with risk of minor drug reactions when treated with carbamazepine in children.	no		11	10	Multiple groups, Singapore: Chinese, Malay, Indian	Toxicity	true	Minor drug reactions included maculopapular exanthema and urticaria. No significant difference in the frequency of the *15:02 allele was seen between children with carbamazepine-induced minor drug reactions and carbamazepine-tolerant controls.	carbamazepine
1448260980	HLA-B*15:02:01	PMID:21428768	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	< 0.001	4877		East Asian	Toxicity	false	This study demonstrated that prospective screening for the *15:02 allele was highly effective at preventing Stevens-Johnson Syndrome/toxic epidermal necrolysis in people taking carbamazepine.	carbamazepine
1184746938	HLA-B*48:01:01	PMID:19002350	HLA-B	HLA-B *48:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with allopurinol or carbamazepine in people with severe cutaneous adverse reactions.	no		6	16	East Asian	Toxicity	false	The frequency of the *4801 allele amoungst patients with DIHS/DRESS was higher compared to the frequency reported for the general population (4.3%) but was not statistically significant after correction for multiple comparisons.	allopurinol; carbamazepine
1448612735	HLA-B*07:02:01; HLA-B*15:21	PMCID:PMC5372085	HLA-B	HLA-B *15:21 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine as compared to HLA-B *07:02:01.	yes	= 0.003	13	225	Multiple groups, Japanese, European, Korean, Canadian	Toxicity	false		carbamazepine
1447678304	rs1045642	PMCID:PMC4640545	ABCB1	Genotype AG is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.	yes	< 0.05	145		European	Metabolism/PK	false	The authors evaluated daily dose and maintenance dose and calculated the means for each genotype. The AG genotype is associated with a higher mean daily dose of carbamazepine (CBZ). Mean CBZ daily dose (mg/day) for the AG genotype was 594.4 vs. 440.4-525.4 for the GG and CC genotypes, respectively. There were no significant differences in maintenance dose, however. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
769257715	rs1045642	PMID:16753003	ABCB1	Allele A is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele G.	no		174		East Asian	Metabolism/PK,Other	false	as measured by steady-state CBZ concentration to the dose (C/D) ratios.	carbamazepine
981859247	rs211037	PMCID:PMC3125053	GABRG2	Allele T is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.578	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1183701415	rs6883877	PMID:24236484	GABRA1	Genotype CT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1184407476	HLA-B*08:01:01; HLA-B*27:05:02	PMID:16981842	HLA-B	HLA-B *27:05:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	no	= 0.5914	20	79	European	Toxicity	false	No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *27:05 allele, as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
1447678311	rs2298771	PMCID:PMC4640545	SCN1A	Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	no	> 0.05	145		European	Metabolism/PK	false	In none of the measures that the authors used to measure exposure showed any association with the genotype. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
769257718	rs1128503	PMID:16753003	ABCB1	Allele G is not associated with metabolism of carbamazepine in people with Epilepsy as compared to allele A.	no		174		East Asian	Metabolism/PK,Other	false	as measured by steady-state CBZ concentration to the dose (C/D) ratios.	carbamazepine
981501871	rs4688040	PMCID:PMC3570048	NR1I2	Allele T is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele G.	yes	= 0.04	88		Multiple groups, African Americans and Caucasians	Metabolism/PK	false	This association was significant in the whole cohort. As measured by a higher carbamazepine-10-11 epoxide: carbamazepine ratio.	carbamazepine
1183701437	rs511310	PMID:24236484		Genotype GG is not associated with decreased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype AA.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1447678328	rs1045642	PMCID:PMC4640545	ABCB1	Genotype AG is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + GG.	no	< 0.05	145		European	Metabolism/PK	false	In none of the measures that the authors used to measure exposure showed any association with the genotype.  Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
1184407466	HLA-B*08:01:01; HLA-B*15:01:01:01	PMID:16981842	HLA-B	HLA-B *15:01:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	no	= 0.7656	20	43	European	Toxicity	false	No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *15:01 allele, as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
613977005	rs2227956	PMID:16538175	HSPA1L	Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele A.	yes	= 0.014	22	44	European	Toxicity	false	Allele G was considered protective against severe hypersensitivity. (allele complimented to plus strand)	carbamazepine
1448525667	HLA-A*11:01:01	PMID:27888155	HLA-A	HLA-A *11:01:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.002	2	23	European	Toxicity	false	"The frequency of the HLA-A*11:01 allele was significantly higher in cases of carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to a group of patients tolerant to carbamazepine, as well as a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""), and general population controls."	carbamazepine
1447678334	rs2234922	PMCID:PMC4640545	EPHX1	Genotype GG is not associated with dose of carbamazepine in people with Epilepsy as compared to genotype AA.	no	> 0.05	145		European	Metabolism/PK	false	There was no association between dose (mean daily, or mean maintenance) with the genotype.	carbamazepine
1184999830	rs2298771	PMID:25155934	SCN1A	Genotype CC is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype TT.	no	= 0.253	207	246	East Asian	Efficacy	false	Genotypes of this SNP did not have significantly different frequencies in the drug resistant patients compared to drug responsive patients. Alleles have been complemented to the plus chromosomal strand. Variant described as SCN1A c.3184A>G.	carbamazepine; oxcarbazepine
981501880	rs3814055	PMCID:PMC3570048	NR1I2	Allele T is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to allele C.	yes	= 0.04	30		African American/Afro-Caribbean	Metabolism/PK	false	This association was only significant in the African American patients and not in Caucasian patients.	carbamazepine
1184407457	HLA-B*08:01:01; HLA-B*51:01:01	PMID:16981842	HLA-B	HLA-B *51:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	no	= 0.4161	20	43	European	Toxicity	false	No significant change in the risk for developing of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n= 18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)) was seen in patients carrying the *51:01 allele, as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
1447678320	rs2298771	PMCID:PMC4640545	SCN1A	Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	no	> 0.05	145		European	Metabolism/PK	false	There was no association between dose (mean daily, or mean maintenance) with the genotype. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
1449295707	HLA-A*31:01:02	PMID:29610831	HLA-A	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms, Erythema multiforme NOS, Hypersensitivity and Maculopapular Exanthema when treated with carbamazepine in people with Bipolar Disorder, Epilepsy, Neuralgia or Schizophrenia.	not stated		932	198	East Asian	Toxicity	false		carbamazepine
981501889	rs28365063	PMCID:PMC3570048	UGT2B7	Genotype AA is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to genotypes AG + GG.	yes	= 0.004	30		African American/Afro-Caribbean	Metabolism/PK	false	This association was only significant in the African American patients and not in Caucasian patients.	carbamazepine
1184466909	HLA-A*31:01:02	PMCID:PMC3113609	HLA-A	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	yes	= 0.03	27	257	European	Toxicity	false	Hypersensitivity syndrome defined as the presence of a rash or liver involvement within 3 months after initiation of carbamazepine treatment, along with a minimum of two of the following manifestations: prolonged recovery phase despite drug withdrawal, fever, involvement of other internal organs, or presence of hematologic abnormalities. Patients who experienced carbamazepine-induced hypersensitivity syndrome had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.	carbamazepine
1184467933	HLA-B*15:02:01	PMID:21917426	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.042	7	485	East Asian	Toxicity	false	14.3% of patients with carbamazepine-induced Stevens-Johnson Syndrome (SJS) carried the allele, as compared to 0.4% of the healthy population controls. However, no significant results were seen when comparing allele frequencies between patients with SJS and carbamazepine-tolerant controls (frequency = 0%).	carbamazepine
1447678220	rs3812718	PMCID:PMC4640545	SCN1A	Genotype TT is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	= 0.002	145		European	Metabolism/PK	false	The authors evaluated maintenance dose-adjusted concentrations of carbamazepine (CBZ), its active metabolite, CBZ-epoxide (CBZE), and its inactive metabolite CBZ-diol (CBZD) as well as CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios. The TT genotype is associated with a lower mean dose adj. concentration of CBZ (microgram/mL per mg/Kg) (0.71 for the TT genotype vs. 0.92-1.11 for the CT and CC genotypes, respectively) as well as a higher mean CBZD:CBZ (0.43 for TT vs. 0.23-0.27 for the CT and CC genotypes, respectively). Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
1184421854	HLA-B*15:02:01	PMID:20833111	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes		8	71	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=3) and toxic epidermal necrolysis (TEN; n=5). 8/8 patents with carbamazepine-induced SJS or TEN (case) carried the *15:02 allele, as compared to 4/50 carbamazepine-tolerant controls (control) and 6/71 healthy volunteers (control).	carbamazepine
613978577	rs1045642	PMCID:PMC556232	ABCB1	Allele A is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele G.	no					Dosage,Metabolism/PK	false		carbamazepine
769146001	rs2032582	PMID:20417680	ABCB1	Allele C is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele T.	no		228		Central/South Asian	Efficacy	false	"This is a three allele SNP.  No association was found between any of the three alleles (C,T,A) and response to antiepileptic drugs.
Subjects on the different medications were pooled."	carbamazepine; phenobarbital; phenytoin; valproic acid
1184466899	HLA-B*15:02:01	PMID:21424386	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.0001	17	185	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The *15:02 allele was present in 94.1% (16/17) of individuals with carbamazepine-induced SJS/TEN, as compared to 9.5% (2/21) of carbamazepine-tolerant controls, and 9.2% (17/185) of healthy individuals.	carbamazepine
1183701441	rs4828696	PMID:24236484	GABRA3	Genotype TT is not associated with increased response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype CC.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction. However, when multiple variants were analyzed together a significant association was seen in logistic regression analysis of factors related to epilepsy treatment outcome; age, mesial temporal sclerosis vs unidentified, temporal lobe epilepsy, rs6883877, rs511310, and rs4828696 (p<0.0001).	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1184468437	HLA-A*31:01:02	PMID:24268988	HLA-A	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	yes	= 2.4E-3	23	152	East Asian	Toxicity	false	Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). Patients with carbamazepine-induced MPE or DRESS had an increased frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.	carbamazepine
769146005	rs1045642	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		282		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184467926	HLA-A*31:01:02	PMID:21917426	HLA-A	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 4.2E-7	17	485	East Asian	Toxicity	false	Severe cutaneous adverse reactions (SCARs) included hypersensitivity syndrome (n=17) and Stevens-Johnson Syndrome (SJS; n=7). 54% of those with carbamazepine-induced SCARs carried the *31:01 allele, as compared to 14% of carbamazepine-tolerant controls, and 10% of healthy population controls.	carbamazepine
1449004817	HLA-B*15:21	PMCID:PMC5753619	HLA-B	HLA-B *15:21 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	no	= 0.55	12	17	East Asian	Toxicity	false	The allele frequency for HLA-B*15:21 was not significantly higher in CBZ-induced SJS/TEN vs population controls and vs drug tolerant controls. However, this allele (along with others) is part of the HLA-B75 serotype, which was significantly associated with SJS/TEN in this population.	carbamazepine
1184466889	HLA-B*15:02:01	PMID:21397523	HLA-B	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with carbamazepine.	no	= 0.11	39	80	East Asian	Toxicity	false	No significant difference in the frequency of the *15:02 allele was seen between patients with carbamazepine-induced maculopapular eruption (MPE) and carbamazepine-tolerant controls. 25.64% (10/39) of patients with MPE had the allele, as compared to 13.75% (11/80) of carbamazepine-tolerant individuals.	carbamazepine
1184467913	HLA-A*31:01:02	PMID:21917426	HLA-A	HLA-A *31:01:02 is associated with increased risk of Drug Hypersensitivity when treated with carbamazepine.	yes	= 2.9E-6	17	485	East Asian	Toxicity	false	Hypersensitivity syndrome, with diagnostic criteria being skin rash, plus two of fever, lymphadenopathy, and hematologic abnormalities, with the involvement of at lest one internal organ. 59% of those with carbamazepine-induced hypersensitivity syndrome carried the *31:01 allele, as compared to 14% of carbamazepine-tolerant controls, and 10% of healthy population controls.	carbamazepine
1183701468	rs1112122	PMID:24236484	GABRA3	Genotype GG is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.04	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1446895471	HLA-B*15:02:01	PMID:26319500	HLA-B	HLA-B *15:02:01 is associated with Epidermal Necrolysis, Toxic when treated with carbamazepine.	not stated		1		East Asian	Toxicity	false	Case report. A 28-year-old Malaysian Australian man of Han Chinese descent developed toxic epidermal necrolysis 2 weeks after commencing carbamazepine treatment. He was subsequently found to have the HLA-B*15:02 allele.	carbamazepine
1183701464	rs10068980	PMID:24236484	GABRA1	Genotype AA is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype GG.	no	< 0.02	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
769145998	rs1128503	PMID:20417680	ABCB1	Allele A is not associated with increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in people with Epilepsy as compared to allele G.	no		228		Central/South Asian	Efficacy	false	Subjects on the different medications were pooled.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184746954	HLA-B*13:01:01	PMID:19002350	HLA-B	HLA-B *13:01:01 is associated with Drug Hypersensitivity and drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine, phenobarbital or phenytoin in people with severe cutaneous adverse reactions.	no		4	16	East Asian	Toxicity	false	The frequency of the *1301 allele (25%) was higher compared to the frequency reported for the general population (1.3%) but was not statistically significant after correction for multiple comparisons.	carbamazepine; phenobarbital; phenytoin
1184468430	HLA-B*40:01:01	PMID:24268988	HLA-B	HLA-B *40:01:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 8.3E-5	112	152	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a decreased frequency of the *40:01 allele, as compared to carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.	carbamazepine
1184988662	HLA-B*15:02:01	PMID:24897291	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	< 0.0001	251	832	East Asian	Toxicity	false	Meta-analysis with 15 studies. Cases were compared against drug-tolerant controls.	carbamazepine
1444935495	rs1045642	PMID:25495409	ABCB1	Genotype GG is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotype AG.	yes	= 0.001	210		East Asian	Metabolism/PK	false	Patients with the GG genotype had increased dose-adjusted concentrations of carbamazepine as compared to those with the AG genotype, as well as increased dose-adjusted concentrations of the carbamazepine metabolites carbamazepine-10,11-epoxide (CBZE) and carbamazepine-10,11-trans dihydrodiol (CBZD). Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
1450968868	HLA-B*51:01:01	PMCID:PMC6989248	HLA-B	HLA-B *51:01:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	"This allele was present in 3 of 5 cases alongside other HLA alleles. Case 1: HLA-A*02:01/*26:01, HLA-B*15:11/*51:01, HLA-C*03:04/*15:02; Case2: HLA-A*24:02/*26:02, HLA-B*51:01/*51:01, HLA-C*14:02/*14:02; Case 3 : HLA-A*02:01/*02:01, HLA-B*35:01/*51:01, HLA-C*03:04/*14:02. Authors state ""Korean allele frequencies of the five cases' common alleles were 9.54% for -B*51:01""."	carbamazepine; phenytoin
613977025	rs1043620	PMID:16538175	HSPA1A	Allele T is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele C.	yes	= 0.011	22	172	European	Toxicity	false	Allele T was considered protective against severe hypersensitivity.	carbamazepine
1183701460	rs6892782	PMID:24236484	GABRA1	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.01	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1184466880	HLA-B*15:02:01	PMID:21397523	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.001	9	80	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=8) and toxic epidermal necrolysis (TEN; n=1). The frequency of the *15:02 allele was 100% (9/9) in patients with carbamazepine-induced SJS/TEN as compared to 13.75% in carbamazepine-tolerant controls (11/80) and 17.74% in healthy individuals (11/62).	carbamazepine
1183701456	rs1157122	PMID:24236484	GABRA1	Genotype CC is not associated with response to carbamazepine, gabapentin, lamotrigine, oxcarbazepine, phenytoin, topiramate or valproic acid in people with Epilepsy as compared to genotype TT.	no	< 0.02	349	371	East Asian	Efficacy	false	The association was not significant after Bonferroni correction.	carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; topiramate; valproic acid
1184468423	HLA-B*15:02:01	PMID:24268988	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 5.8E-43	112	152	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had an increased frequency of the *15:02 allele, as compared to carbamazepine-tolerant controls. Results were also significant when considering only patients with TEN, SJS/TEN overlap, SJS, SJS with 6-9% area of skin detachment, SJS with 2-5% area of skin detachment, and SJS with <= 1% area of skin detachment; refer to paper for p-values and odds ratios. Adjusted p-values using Bonferroni's correction.	carbamazepine
827824182	rs28365062	PMID:22188362	UGT2B7	Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1184468477	HLA-B*15:02:01	PMID:24268988	HLA-B	HLA-B *15:02:01 is not associated with risk of Drug Hypersensitivity when treated with carbamazepine.	no	> 0.05	74	152	East Asian	Toxicity	false	Drug hypersensitivity included maculopapular eruption (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS). No significant difference in the frequency of the *15:02 allele was seen between those with carbamazepine-induced MPE or DRESS and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.	carbamazepine
827824178	rs7668258	PMID:22188362	UGT2B7	Allele T is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele C.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1183613417	rs17183814	PMID:23859570	SCN2A	Allele A is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.64	1766		Multiple groups	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs.	carbamazepine; valproic acid
827824191	rs7438135	PMID:22188362	UGT2B7	Allele G is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele A.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1451305960	HLA-B*15:02:01	PMID:33356553	HLA-B	HLA-B *15:02:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.0001	41	46		Toxicity	false	but not associated with increased risk of DIHS/DRESS	carbamazepine
1184466933	HLA-B*15:02:01	PMID:21676164	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine in people with neuropathic pain.	yes	< 0.001	34	40	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The HLA-B*15:02 allele was present in 94.1% (32/34) of patients with carbamazepine-induced SJS/TEN, but only in 17.5% (7/40) of carbamazepine-tolerant controls.	carbamazepine
827824186	rs7439366	PMID:22188362	UGT2B7	Allele C is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T.	no		234		East Asian	Dosage,Metabolism/PK	false	and not associated with In concentration/dose ratio.	carbamazepine
1184467956	HLA-A*02:01:01:01	PMID:21917426	HLA-A	HLA-A *02:01:01:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	24	50	East Asian	Toxicity	false	Where severe cutaneous adverse reactions (SCARs) included Stevens-Johnson Syndrome (SJS, n=7) and hypersensitivity syndrome (HSS, n=17; see paper for definition). No significant difference in allele frequencies was seen between patients with SJS (42.9%), HSS (17.6%) or SCARs (25%) and carbamazepine-tolerant controls (28%).	carbamazepine
1444935535	rs776746	PMID:25495409	CYP3A5	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	yes	= 0.01	210		East Asian	Metabolism/PK	false	Patients with the CC genotype (also known as CYP3A5 *3/*3) had increased dose-adjusted concentrations of carbamazepine as compared to those with the CT or TT genotype (CYP3A5 *1/*3 or *1/*1). Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
1184466922	HLA-A*31:01:02	PMCID:PMC3113609	HLA-A	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 8.0E-5	12	257	European	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). 42% (5/9) of subjects with carbamazepine-induced SJS/TEN carried the *31:01 allele, as compared to 4% (10/257) of carbamazepine-tolerant controls.	carbamazepine
1450968840	HLA-A*31:01:02	PMCID:PMC6989248	HLA-A	HLA-A *31:01:02 is associated with increased likelihood of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	This allele was present in 1 of 5 cases alongside other HLA alleles. Case 5: HLA-A*24:02/*31:01, HLA-B*07:02/*58:01, HLA-C*03:02/*07:02.	carbamazepine
1447678268	rs2234922	PMCID:PMC4640545	EPHX1	Genotype GG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	yes	= 0.039	145		European	Metabolism/PK	false	The authors evaluated maintenance dose-adjusted concentrations of carbamazepine (CBZ), its active metabolite, CBZ-epoxide (CBZE), and its inactive metabolite CBZ-diol (CBZD) as well as CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios. The GG genotype is associated with a lower mean dose adj. CBZD concentration (microgram/mL per mg/Kg) (0.13 for the GG genotype vs. 0.21-0.24 for the AG and GG genotypes, respectively). The GG genotype also had a lower mean CBZD:CBZ (0.13 for GG vs. 0.24-0.26 for the AG and AA genotypes, respectively). Finally, the GG genotype was associated with a lower mean CBZD:CBZE  (1.74 for GG vs. 3.95-3.08 for AG and AA, respectively).	carbamazepine
1448635693	HLA-A*31:01:02	PMID:28570299	HLA-A	HLA-A *31:01:02 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.046	63		Central/South Asian	Toxicity	false	Association was only found in Indians but not in Malays or Chinese subjects of the cohort.	carbamazepine
1184467950	HLA-A*31:01:02	PMID:21917426	HLA-A	HLA-A *31:01:02 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.03	7	485	East Asian	Toxicity	false	42.9% of patients with carbamazepine-induced Stevens-Johnson Syndrome (SJS) carried the allele, as compared to 10.3% of the healthy population controls. However, no significant results were seen when comparing allele frequencies between patients with SJS and carbamazepine-tolerant controls (frequency = 14%).	carbamazepine
613978592	rs3812718	PMCID:PMC556232	SCN1A	Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	yes	= 0.0051	425		European	Dosage	false		carbamazepine
1184468448	HLA-A*31:01:02	PMID:24268988	HLA-A	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	> 0.05	112	152	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). No significant difference in the frequency of the *31:01 allele was seen between those with carbamazepine-induced SJS or TEN and carbamazepine-tolerant controls. Adjusted p-values using Bonferroni's correction.	carbamazepine
1449004837	HLA-B*18:01:01	PMCID:PMC5753619	HLA-B	HLA-B *18:01:01 is associated with increased likelihood of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	no	= 0.06	12	236	East Asian	Toxicity	false	Allele frequency was higher in CBZ-induced SJS/TEN vs population controls and vs drug tolerant controls but not significant.	carbamazepine
1444935523	rs2242480	PMID:25495409	CYP3A4	Genotype CC is associated with increased concentrations of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	yes	= 0.027	210		East Asian	Metabolism/PK	false	Patients with the CC genotype (also known as CYP3A4 *1/*1) had increased dose-adjusted concentrations of carbamazepine as compared to those with the CT or TT (CYP3A4 *1/*1G or *1G/*1G) genotype, as well as increased dose-adjusted concentrations of the carbamazepine metabolite carbamazepine-10,11-epoxide (CBZE). Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
1451504120	HLA-B*15:11:01	PMID:34553372	HLA-B	HLA-B *15:11:01 is associated with increased likelihood of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 0.048	23	47	East Asian	Toxicity	false	Authors looked at SCARs in patients who are HLA-B*15:02 negative but HLA-B*15:11 positive	carbamazepine
1184466916	HLA-A*31:01:02	PMCID:PMC3113609	HLA-A	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	yes	= 8.0E-7	106	257	European	Toxicity	false	Patients with carbamazepine-induced maculopapular exanthema had an increased frequency of *31:01, as compared to carbamazepine-tolerant controls.	carbamazepine
1184467942	HLA-B*15:11:01	PMID:21917426	HLA-B	HLA-B *15:11:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.002	7	485	East Asian	Toxicity	false	42.9% of patients with carbamazepine-induced Stevens-Johnson Syndrome (SJS) carried the allele, as compared to 3.9% of healthy population controls. However, no significant results were seen when comparing allele frequencies between patients with SJS and carbamazepine-tolerant controls (frequency = 4%).	carbamazepine
1184999713	rs2273697	PMID:25155934	ABCC2	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.007	207	246	East Asian	Efficacy	false	The AG genotype was more frequent in the drug resistant patients. The AA genotype was not found at a statistically higher frequency in patients with drug resistance (lack of association with this genotype may be due to low frequency). Remained significant after Bonferroni correction of p<0.041.	carbamazepine; oxcarbazepine
1184469272	HLA-A*31:01:02	PMID:24322785	HLA-A	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.001	36	579	European	Toxicity	false	Meta-analysis. Severe cutaneous adverse reactions were Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Patients with carbamazepine-induced SJS or TEN had a higher frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls, in a European population (3 studies) and a European and Asian combined population (8 studies), but NOT in an exclusively Asian population (5 studies).	carbamazepine
1448266704	rs1128503	PMID:26421491	ABCB1	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	no	= 0.411			East Asian	Metabolism/PK	false		carbamazepine
1184468253	HLA-DRB1*03:01:01:01	PMID:23830818	HLA-DRB1	HLA-DRB1 *03:01:01:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.	yes	= 0.024	40	52	East Asian	Toxicity	false	Patients with carbamazepine-induced maculopapular eruption had a lower frequency of the *03:01 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.	carbamazepine
1448266710	rs15524	PMID:26421491	CYP3A5	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	no	= 0.357			East Asian	Metabolism/PK	false		carbamazepine
981954817	rs2032582	PMID:18812236	ABCB1	Genotype AA is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1444935576	rs3738046	PMID:25495409	EPHX1	Genotype CG is associated with concentrations of carbamazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.017	210		East Asian	Metabolism/PK	false	A significantly higher carbamazepine-10,11-trans dihydrodiol (CBZD):carbamazepine-10,11-epoxide (CBZE) ratio was observed in patients with the CG genotype as compared to those with the GG genotype.	carbamazepine
1448612304	HLA-A*31:01:02	PMID:28340402	HLA-A	HLA-A *31:01:02 is associated with Exanthema when treated with carbamazepine in people with Epilepsy.	not stated		1		Unknown	Toxicity	false	Case report. A 27-year-old German woman of Pakistani descent developed epilepsy. She was given carbamazepine, and presented with generalized maculopapular exanthema three weeks later. The patient was reinitiated on eslicarbazepine with no adverse effects. HLA testing revealed the patient had HLA-A*31:01.	carbamazepine
981954829	rs1045642	PMID:18812236	ABCB1	Allele G is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy as compared to allele A.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1448266716	rs776746	PMID:26421491	CYP3A5	Allele C is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.	no	= 0.356			East Asian	Metabolism/PK	false		carbamazepine
1184468246	HLA-DRB1*14:05:01	PMID:23830818	HLA-DRB1	HLA-DRB1 *14:05:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	yes	= 0.003	40	52	East Asian	Toxicity	false	Patients with carbamazepine-induced maculopapular eruption had a higher frequency of the *14:05 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.	carbamazepine
981954839	rs2032582	PMID:18812236	ABCB1	Genotype AT is not associated with response to carbamazepine, phenobarbital, phenytoin or valproic acid in people with Epilepsy.	no		94	231	Central/South Asian	Efficacy	false	Of 325 patients with epilepsy, 94 were drug resistant and 231 were drug responsive.  Results from patients on the different drugs were pooled.  There were also 101 control subjects (no epilepsy).	carbamazepine; phenobarbital; phenytoin; valproic acid
1444935567	rs2234922	PMID:25495409	EPHX1	Genotypes AG + GG is associated with concentrations of carbamazepine in people with Epilepsy as compared to genotype AA.	yes	= 0.039	210		East Asian	Metabolism/PK	false	Patients with the AG or GG genotype had significantly lower dose-adjusted concentrations of the carbamazepine metabolite carbamazepine-10,11-trans dihydrodiol (CBZD) as compared to those with the AA genotype, as well as a significantly lower CBZD:CBZE ratio as compared to those with the AA genotype (CBZE = another carbamazepine metabolite, carbamazepine-10,11-epoxide).	carbamazepine
613976841	rs2894342	PMID:16538176	MLN	Allele A is associated with increased risk of Hypersensitivity Syndrome when treated with carbamazepine as compared to allele C.	yes	= 0.0064	13	144	East Asian	Toxicity	false		carbamazepine
1184466701	HLA-A*31:01:02	PMID:21149285	HLA-A	HLA-A *31:01:02 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 3.64E-15	61	376	East Asian	Toxicity	false	Severe cutaneous adverse reactions (cADRs) included Stevens-Johnson Syndrome and  toxic epidermal necrolysis (SJS/TEN; n=5), drug-induced hypersensitivity syndrome (DIHS; n=21), and various others (e.g. erythema multiforme; n=19) The *31:01 allele was present in 37/61 (60.7%) of patients with carbamazepine-induced cADRs, but only 47/376 (12.5%) of carbamazepine-tolerant controls. p-value for significance was set at 0.00263 (0.05/19). This association was replicated in a smaller cohort of 16 cases and 44 controls (p-value for significance set at 0.025 (0.05/2).	carbamazepine
1184469261	HLA-A*31:01:02	PMID:24322785	HLA-A	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	yes	< 0.001	119	1291	"Multiple groups, European and Asian (Chinese, Korean, Japanese, ""Asia"" unspecified)"	Toxicity	false	Meta-analysis. Patients with carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) had a higher frequency of the *31:01 allele, as compared to carbamazepine-tolerant controls in European (3 studies) and Asian (5 studies) populations, and both populations combined (8 studies).	carbamazepine
1184468239	HLA-B*58:01	PMID:23830818	HLA-B	HLA-B *58:01 is associated with decreased risk of Maculopapular Exanthema when treated with carbamazepine.	yes	= 0.037	40	52	East Asian	Toxicity	false	Patients with carbamazepine-induced maculopapular eruption had a lower frequency of the *58:01 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.	carbamazepine
1444935560	rs776746	PMID:25495409	CYP3A5	Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	yes	= 0.039	210		East Asian	Dosage	false	Patients with the CC genotype (also known as CYP3A5 *3/*3) were more likely to require a higher carbamazepine maintenance dose as compared to those with the CT or TT genotype (CYP3A5 *1/*3 or *1/*1). Please note alleles have been complemented to the plus chromosomal strand.	carbamazepine
981859101	HLA-B*15:02:01	PMID:17509004	HLA-B	HLA-B *15:02:01 is not associated with increased risk of maculopapular exanthema when treated with antiepileptics or carbamazepine in Epilepsy.	no	= 0.32	24	48	East Asian	Toxicity	false		antiepileptics; carbamazepine
1448266698	rs10234411	PMID:26421491	ABCB1	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.	no	= 0.393			East Asian	Metabolism/PK	false		carbamazepine
1184468229	HLA-A*02:01:01:01	PMID:23830818	HLA-A	HLA-A *02:01:01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	yes	= 0.033	40	52	East Asian	Toxicity	false	Patients with carbamazepine-induced maculopapular eruption had a higher frequency of the *02:01 allele, as compared to those who were carbamazepine-tolerant. However, no significant association was seen when comparing against healthy population controls.	carbamazepine
1184999741	rs2273697	PMID:25155934	ABCC2	Genotype AG is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype GG.	no	= 0.036	170	156	East Asian	Efficacy	false	The AG genotype was more frequent in the drug resistant patients. The AA genotype was not found at a statistically higher frequency in patients with drug resistance (lack of association with this genotype may be due to low frequency). Was not significant after Bonferroni correction of p<0.041.	carbamazepine; oxcarbazepine
981859096	HLA-B*15:02:01	PMID:17509004	HLA-B	HLA-B *15:02:01 is associated with increased risk of cutaneous reactions when treated with antiepileptics or carbamazepine in Epilepsy.	yes	= 0.001	24	48	East Asian	Toxicity	false		antiepileptics; carbamazepine
1448261069	HLA-B*15:02:01	PMID:25355835	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.027	111242		Multiple groups, Mixed Asian (Hong Kong)	Toxicity	false	This study demonstrated that prospective screening for *15:02 prevented the occurrence of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in people taking carbamazepine. However, this may have been due to avoidance of the drug entirely rather than taking into account pharmacogenetic information.	carbamazepine
1184468281	HLA-A*24:02:01:01	PMID:22348435	HLA-A	HLA-A *24:02:01:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 0.03	18	264	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) or toxic epidermal necrolysis (TEN; n=1). Patients who experienced carbamazepine-induced SJS or TEN had an increased frequency of the *24:02 allele, as compared to carbamazepine-tolerant controls or healthy population controls. Note that p-values not adjusted for multiple comparisons.	carbamazepine
1444935614	HLA-A*01:01:01:01	PMID:25495410	HLA-A	HLA-A *01:01:01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	yes	= 0.0074	5	225	Latino	Toxicity	false	The frequency of the HLA-A*01:01:01 allele in the carbamazepine-induced maculopapular exanthema group was higher than that in the general Mexican Mestizo population. Corrected p-value. Significant results were also see when compared against carbamazepine-tolerant controls (n=18), but only before correction of the p-value (p=0.028; OR=7.29 (1.02 - 52.01)).	carbamazepine
1447678444	rs1051740	PMID:26314341	EPHX1	Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT.	no		166		East Asian	Dosage,Metabolism/PK	false	This was not significant after bonferroni correction. This SNP was also associated with concentration dose ratio in multivariate analysis and associated with metabolite CBZ 10,11-epoxide (CBZE) concentration.	carbamazepine
981501734	rs2740574	PMCID:PMC3570048	CYP3A4	Genotype TT is associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	= 0.027	88		Multiple groups, African Americans and Caucasians	Metabolism/PK	false	This association was significant in the whole cohort, but not when looking at African American or Caucasian patient sub-cohorts. The C allele occured at a higher frequency in African Americans compared to Caucasians, and the authors suggest that this association may be due to differences in the racial groups (African Americans had a significantly lower clearance p=0.006 and longer half-life p=0.01 of the drug as compared with Caucasians).	carbamazepine
1447678447	rs2234922	PMCID:PMC4640545	EPHX1	Genotype AA is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes AG + GG.	no	= 0.79	145		European	Efficacy	false	The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups.	carbamazepine
981859117	HLA-B*15:02:01	PMID:22500513	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine or phenytoin in people with Epilepsy.	not stated		14	16	East Asian	Toxicity	false		carbamazepine; phenytoin
994166507	HLA-B*15:02:01	PMCID:PMC3839910	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.	yes	= 0.002	42	91	Multiple groups	Toxicity	true		carbamazepine
1447678435	rs1051740	PMCID:PMC4640545	EPHX1	Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	no	= 0.97	145		European	Efficacy	false	The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups.	carbamazepine
1451271980	HLA-B*15:02:01	PMCID:PMC5467955	HLA-B	HLA-B *15:02:01 is associated with risk of Epidermal Necrolysis, Toxic or Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin.	yes	= 5.63e-15	56	179	East Asian	Toxicity	true	in pooled analysis (all 3 drugs) this was a clear association. Authors suggest this is driven by carbamazepine.	carbamazepine; lamotrigine; phenytoin
1451407660	HLA-B*15:21	PMID:31896765	HLA-B	HLA-B *15:21 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy, Mood Disorders or neuropathic pain.	yes	= 0.026	8	32	"Multiple groups, Excerpt from paper: ""All of the patients were considered as pure Filipinos except for five patients (one case and four tolerant controls) who were considered as mixed Filipinos. One case and two tolerant controls have Chinese descent. The other tolerant controls have German, Indian, and Spanish lineage."""	Toxicity	false	HLA-B75 serotype (includes HLA-B*15:21) was significantly associated with increased SJS/TEN risk (OR 23.25, 95% CI 2.33-232.21, p=0.007)	carbamazepine
1184422696	HLA-B*15:02:01	PMID:20833111	HLA-B	HLA-B *15:02:01 is not associated with risk of Maculopapular Exanthema when treated with carbamazepine.	no	= 0.697	28	50	East Asian	Toxicity	false	No significant increase in risk for maculopapular eruption (MPE) was seen for patients carrying the *15:02 allele. 3/28 patients with MPE carried the allele, compared to 4/50 carbamazepine-tolerant controls and 6/71 healthy volunteers.	carbamazepine
1448266722	rs4646440	PMID:26421491	CYP3A4	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	no	= 0.765			East Asian	Metabolism/PK	false		carbamazepine
981501747	CYP3A5*1; CYP3A5*3	PMCID:PMC3570048	CYP3A5	CYP3A5 *3/*3 is associated with decreased clearance of carbamazepine in people with Epilepsy as compared to CYP3A5 *1/*1 + *1/*3.	yes	= 0.037	30		African American/Afro-Caribbean	Metabolism/PK	false	as measured by a greater half-life. This association was only significant in the African American sub-cohort and not in Caucasian patients. The *3 allele occurred at a lower frequency in African Americans compared to Caucasians.	carbamazepine
1184746798	rs3130501	PMCID:PMC3173287	POU5F1	Allele G is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele A.	yes	= 1.73E-8	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin
1447678461	rs2298771	PMCID:PMC4640545	SCN1A	Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	no	= 0.97	145		European	Metabolism/PK	false	The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups. Please note: alleles have been complemented to the + chromosomal strand.	carbamazepine
981501753	rs1051740	PMCID:PMC3570048	EPHX1	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT.	yes	= 0.026	30		African American/Afro-Caribbean	Metabolism/PK	false	as measured by a lower carbamazepine-10,11-transdihydrodiol:carbamazepine-10-11 epoxide metabolite ratio. This association was only significant in the African American patients and not in Caucasian patients.	carbamazepine
1296598769	HLA-A*02:01	PMID:22211527	HLA-A	HLA-A *02:01 is associated with decreased risk of Drug Toxicity when treated with carbamazepine.	yes	= 0.04	15	33	East Asian	Toxicity	false	Patients with carbamazepine-induced adverse drug reactions had a lower frequency of the HLA-A*02 allele as compared to carbamazepine-tolerant patients. Note that this annotation was done on HLA-A*02:01 because this was the first *02 allele discovered.	carbamazepine
1448266728	rs2242480	PMID:26421491	CYP3A4	Allele C is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele T.	no	= 0.723			East Asian	Metabolism/PK	false		carbamazepine
1296599283	rs717620	PMID:24567120	ABCC2	Genotypes CT + TT is not associated with response to carbamazepine in people with Epilepsies, Partial as compared to genotype CC.	no	= 0.650	134		Unknown	Efficacy	false	The rs717620 SNP did not affect time to 12-month remission. While it showed a significant effect on time to first seizure (p=0.034), this result was no longer significant after applying Bonferroni correction for multiple comparisons (pc=1.0). Please note that alleles have been complemented to the plus chromosomal strand.	carbamazepine
769171557	rs2304016	PMID:18784617	SCN2A	Allele A is associated with drug resistance when treated with carbamazepine, lamotrigine, oxcarbazepine, phenytoin or topiramate in people with Epilepsy as compared to allele G.	yes	= 0.02	177	200	East Asian	Efficacy	false		carbamazepine; lamotrigine; oxcarbazepine; phenytoin; topiramate
655388335	rs1800629	PMID:11294926	LTA; TNF	Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G.	yes	= 0.02	23	63	Multiple groups, All the patients were white, apart from three (one Indian, one Yemeni, one half-Thai). All of these control subjects were white.	Toxicity	false	(was not associated with nonserious hypersensitivity, ie. nonserious maculopapular skin rashes that subsided on discontinuation of CBZ, without the need for further therapy)	carbamazepine
1296598666	HLA-A*31:01:02	PMID:22211527	HLA-A	HLA-A *31:01:02 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	yes	= 0.001	15	33	East Asian	Toxicity	false	Patients with carbamazepine-induced adverse drug reactions had a greater frequency of the HLA-A*31 allele as compared to carbamazepine-tolerant patients. Note that this annotation was done on HLA-A*31:01:02 because this was the first *31 allele discovered. The authors also note that the HLA-A*31 allele does not determine carbamazepine-induced lymphocyte proliferation.	carbamazepine
981859149	rs1045642	PMCID:PMC3125053	ABCB1	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.39	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1447980932	HLA-B*15:02:01	PMID:27096699	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic, Exanthema and Stevens-Johnson Syndrome when treated with carbamazepine in people with Bipolar Disorder or Epilepsy.	yes	= 0.0002	23	63	East Asian	Toxicity	false		carbamazepine
1447678341	rs1051740	PMCID:PMC4640545	EPHX1	Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT.	no	> 0.05	145		European	Metabolism/PK	false	There was no association between dose (mean daily, or mean maintenance) with the genotype.	carbamazepine
1444935634	HLA-A*31:01:02	PMID:25495410	HLA-A	HLA-A *31:01:02 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	no	= 0.0061	5	18	Latino	Toxicity	false	Only BEFORE p-value correction. The frequency of the HLA-A*31:01:02 allele in the carbamazepine-induced maculopapular exanthema group was higher than that in the carbamazepine tolerant group and in the general Mexican Mestizo population. After p-value correction the p-values were 0.0619 and 0.1773, respectively, for these associations.	carbamazepine
1448525723	HLA-A*31:01:02	PMID:27888155	HLA-A	HLA-A *31:01:02 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	yes	= 0.006	4	253	European	Toxicity	false	"The frequency of the HLA-A*31:01 allele was significantly higher in cases of carbamazepine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to a group of patients tolerant to carbamazepine, as well as a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""), and general population controls."	carbamazepine
1184468310	HLA-A*31:01:02	PMID:22348435	HLA-A	HLA-A *31:01:02 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine.	no	= 0.33	18	32	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) and toxic epidermal necrolysis (TEN; n=1). No significant differences in the frequencies of the *31:01 allele were seen between those with carbamazepine-induced SJS or TEN, and carbamazepine-tolerant controls or healthy population controls. Note that p-values not adjusted for multiple comparisons.	carbamazepine
981501779	rs2234922	PMCID:PMC3570048	EPHX1	Genotype GG is not associated with clearance of carbamazepine in people with Epilepsy as compared to genotypes AA + AG.	no		88		Multiple groups, African Americans and Caucasians	Metabolism/PK	false		carbamazepine
993944301	HLA-A*31:01:02	PMCID:PMC3839910	HLA-A	HLA-A *31:01:02 is not associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in children.	no	= 1.0	42	91	Multiple groups	Toxicity	true		carbamazepine
981751120	rs17183814	PMCID:PMC2767285	SCN2A	Allele A is associated with resistance to carbamazepine, phenobarbital, phenytoin or valproic acid as compared to allele G.	yes	= 0.06	336	160	Central/South Asian	Efficacy	false	p value was above significance level after correction for multiple testing.  Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenobarbital; phenytoin; valproic acid
1184468301	HLA-B*15:11:01	PMID:22348435	HLA-B	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 0.01	18	264	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) and toxic epidermal necrolysis (TEN; n=1). Patients with carbamazepine-induced SJS or TEN had an increased frequency of the *15:11 allele, as compared to healthy population controls. Note that p-values not adjusted for multiple comparisons.	carbamazepine
1448525698	HLA-C*08:01	PMID:27888155	HLA-C	HLA-C *08:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	= 0.003	2	61	European	Toxicity	false	"The frequency of the HLA-C*08:01 allele was significantly higher in cases of carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) as compared to a group of patients tolerant to carbamazepine, as well as a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""), and general population controls."	carbamazepine
1183680856	HLA-B*15:02:01	PMID:23692434	HLA-B	HLA-B *15:02:01 is associated with increased risk of Stevens-Johnson Syndrome when treated with carbamazepine in people with Epilepsy.	yes	= 3.51E-18	26	135	East Asian	Toxicity	false	Stevens-Johnson Syndrome OR toxic epidermal necrolysis (SJS/TEN). Carriers of the HLA-B*15:02 allele have a greater risk of developing SJS/TEN, compared to those without the allele. This study was done in a case-control format, where 26 cases were compared against 135 controls; cases developed SJS/TEN on carbamazepine, controls did not. p < 0.01 was considered significant, after adjustment for multiple comparisons using Bonferroni's correction.	carbamazepine
1185003386	HLA-B*15:02:01	PMID:25266342	HLA-B	HLA-B *15:02:01 is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with carbamazepine.	yes	< 1.0E-4	15	62	Central/South Asian	Toxicity	false	The *15:02 was significantly associated with carbamazepine-induced Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) in an individual analysis, as well as in a pooled-sample analysis and a meta-analysis of two studies. Patients were of Indian background, with those of non-Indian ancestry excluded from the study.	carbamazepine
1448525709	HLA-A*24:02:01:01	PMID:27888155	HLA-A	HLA-A *24:02:01:01 is associated with increased risk of drug reaction with eosinophilia and systemic symptoms when treated with carbamazepine.	yes	= 0.002	3	253	European	Toxicity	false	"The frequency of the HLA-A*24:02 allele was significantly higher in cases of lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to a group of patients tolerant to lamotrigine, as well as a group of patients tolerant to phenytoin, lamotrigine OR carbamazepine (""antiepileptic tolerant controls""), and general population controls."	carbamazepine
1296598677	HLA-A*11:01:01	PMID:22211527	HLA-A	HLA-A *11:01:01 is associated with increased risk of Drug Toxicity when treated with carbamazepine.	yes	= 0.088	15	33	East Asian	Toxicity	false	Patients with carbamazepine-induced adverse drug reactions had a greater frequency of the HLA-A*11 allele as compared to carbamazepine-tolerant patients. Note that this annotation was done on HLA-A*11:01:01 because this was the first *11  allele discovered. The authors note that though the p-value was non-significant, they considered this result significant because the 95% confidence interval (CI) of the odds ratio (OR) did not cross 1 (95% CI = 1.009 - 24.773).	carbamazepine
1184468294	HLA-B*15:02:01	PMID:22348435	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	< 0.001	18	93	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=17) and toxic epidermal necrolysis (TEN; n=1). Patients with carbamazepine-induced SJS or TEN had an increased frequency of the *15:02 allele, as compared to carbamazepine-tolerant patients and healthy population controls. Note that p-values not adjusted for multiple comparisons.	carbamazepine
981501792	rs1128503	PMCID:PMC3570048	ABCB1	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.036	30		African American/Afro-Caribbean	Metabolism/PK	false	This association was only significant in the African American patients and not in Caucasian patients.	carbamazepine
699639378	rs2273697	PMID:20216337	ABCC2	Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.025	47	99	East Asian	Metabolism/PK,Toxicity	false		carbamazepine
1184466811	HLA-A*74:01	PMID:21244392	HLA-A	HLA-A *74:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 0.0408	16	300	East Asian	Toxicity	false	HLA-A*74 was analyzed; specific alleles were not provided. *74:01 was used for this annotation since it was the first *74 allele discovered. Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The *74 allele was present in 3/16 (18.8%) of patients with carbamazepine-induced SJS/TEN, but only 5/300 (1.7%) of normal controls. Bonferroni-corrected p-value.	carbamazepine
981859171	rs1128503	PMCID:PMC3125053	ABCB1	Allele A is not associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	no	= 0.71	402		Central/South Asian	Efficacy	false		carbamazepine; phenytoin; valproic acid
1450968980	HLA-C*03:04:01:01	PMCID:PMC6989248	HLA-C	HLA-C *03:04:01:01 is associated with increased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine or valproic acid in people with Drug Hypersensitivity, severe cutaneous adverse reactions and Epilepsy.	no		5		Unknown	Toxicity	false	"This allele was present in 3 of 5 cases alongside other HLA alleles. Case 1: HLA-A*02:01/*26:01, HLA-B*15:11/*51:01, HLA-C*03:04/*15:02; Case 3 : HLA-A*02:01/*02:01, HLA-B*35:01/*51:01, HLA-C*03:04/*14:02; Case 4 : HLA-A*02:01/*02:10, HLA-B*15:11/*40:06, HLA-C*03:04/*08:01. Authors state ""Korean allele frequencies of the five cases' common alleles were 8.97% for -C*03:04""."	carbamazepine; valproic acid
981501801	rs4148739	PMCID:PMC3570048	ABCB1	Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotype CT.	yes	= 0.023	30		African American/Afro-Caribbean	Metabolism/PK	false	as measured by a lower carbamazepine-10,11-transdihydrodiol:carbamazepine-10-11 epoxide metabolite ratio. This association was only significant in the African American patients and not in Caucasian patients.	carbamazepine
1183611749	rs3812718	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.39	1470		"Multiple groups, 701 patients from Malaysia (Malay, Chinese or Indian), 803 patients from Hong Kong (Han Chinese). "	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction.	carbamazepine; valproic acid
1184407410	HLA-B*07:02:01; HLA-B*08:01:01	PMID:16981842	HLA-B	HLA-B *07:02:01 is associated with decreased risk of severe cutaneous adverse reactions when treated with carbamazepine as compared to HLA-B *08:01:01.	yes	= 0.0099	20	79	European	Toxicity	false	Possession of the *07:02 allele was found to have a protective effect on the development of a severe hypersensitivity reaction (including drug reaction, eosinophilia and systemic symptoms (DRESS; n=18), Stevens-Johnson Syndrome (SJS; n=1) and toxic epidermal necrolysis (TEN; n=1)), as compared to those with two copies of the most common variant allele, *08:01.	carbamazepine
1184466803	HLA-B*15:02:01	PMID:21244392	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 7.87E-6	16	300	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). The *15:02 allele was present in 12/16 (75%) of patients with carbamazepine-induced SJS/TEN, but only 47/300 (15.7%) of normal controls. Bonferroni-corrected p-value.	carbamazepine
1183612769	rs2298771	PMID:23859570	SCN1A	Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C.	no	= 0.81	1448		"Multiple groups, 701 patients from Malaysia (Malay, Chinese or Indian), 803 patients from Hong Kong (Han Chinese). "	Efficacy	false	No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction. Variant described as Thr1067Ala A>G therefore minor allele taken as G (here alleles are complemented for the plus chromosomal strand T>C).	carbamazepine; valproic acid
1448266687	rs2032582	PMID:26421491	ABCB1	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele C.	no	= 0.246			East Asian	Metabolism/PK	false		carbamazepine
981859179	rs2032582	PMCID:PMC3125053	ABCB1	Allele T is associated with drug-resistant phenotype when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele C.	yes	= 0.03	402		Central/South Asian	Efficacy	false	"However, The study reports that the genotype frequencies of 2677G>T ABCB1 polymorphism did not differ significantly in the drug-resistant versus the
drug-responsive epilepsy patients for GT genotype (P =0.71, OR = 1.14, 95% CI = 0.55 - 2.36), for TT genotype (P = 0.87, OR = 1.06, 95% CI = 0.49 - 2.26) and for AT genotype (P = 0.39, OR = 0.53, 95% CI = 0.13 - 2.24). (The alleles are given on the negative strand in the article.)"	carbamazepine; phenytoin; valproic acid
981501809	rs4148740	PMCID:PMC3570048	ABCB1	Genotype AG is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotype AA.	yes	= 0.026	30		African American/Afro-Caribbean	Metabolism/PK	false	as measured by a higher carbamazepine-10,11-transdihydrodiol:carbamazepine-10-11 epoxide metabolite ratio. This association was only significant in the African American patients and not in Caucasian patients.	carbamazepine
1184466792	HLA-B*15:11:01	PMID:21204807	HLA-B	HLA-B *15:11:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes	= 0.0004	28	493	East Asian	Toxicity	false	Severe cutaneous adverse reactions included Stevens-Johnson Syndrome (SJS; n=11) and toxic epidermal necrolysis (TEN; 3). 4/14 (28.5%) of patients with SJS/TEN (including probable SJS patients) carried the *15:11 allele, compared to an allele frequency of 0.01 in the Japanese population.	carbamazepine
1447678392	rs3812718	PMID:26314341	SCN1A	Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC.	no	< 0.05	166		East Asian	Dosage,Metabolism/PK	false	This was not significant after bonferroni correction. This SNP was also associated with concentration dose ratio in multivariate analysis but was not significantly associated with metabolite CBZ 10,11-epoxide (CBZE) concentration.	carbamazepine
1444935657	HLA-B*35:01:01:01	PMID:25495410	HLA-B	HLA-B *35:01:01:01 is associated with increased risk of Maculopapular Exanthema when treated with carbamazepine.	no	= 0.0215	10	28	Latino	Toxicity	false	Only BEFORE p-value correction. The frequency of the HLA-A*35:01:01 allele in the carbamazepine-induced maculopapular exanthema group was higher than that in the carbamazepine tolerant group. After p-value correction the p-value was 0.0537 for this association.	carbamazepine
981501817	rs2273697	PMCID:PMC3570048	ABCC2	Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG.	yes	= 0.047	58		European	Metabolism/PK	false	This association was only significant in Caucasian patients and not in African American patients. It was also associated with higher higher carbamazepine-10-11 epoxide:  carbamazepine ratio in women (p=0.002).	carbamazepine
1184468322	HLA-B*15:02:01	PMID:23884208	HLA-B	HLA-B *15:02:01 is associated with increased risk of severe cutaneous adverse reactions when treated with carbamazepine.	yes		52	2949	Multiple groups, Chinese, Indian, Malaysian, Japanese, Korean, Pakistan, Reunion, Vietnam, Cambodia, Senegal, European	Toxicity	false	Severe cutaneous adverse reactions include Stevens-Johnson Syndrome and toxic epidermal necrolysis. Meta-analysis that included 16 studies. Significant results were also seen when considering only Thai patients (2 studies) and only Han Chinese patients (5 studies).	carbamazepine
1184987994	HLA-B*15:02:01	PMID:23551241	HLA-B	HLA-B *15:02:01 is not associated with risk of severe cutaneous adverse reactions when treated with carbamazepine, phenobarbital or phenytoin in children.	no	= 0.53	40	40	East Asian	Toxicity	true	Carbamazepine n=3, phenobarbital n=20, phenytoin n=17. Children who carried the *15:02 allele did not have an increased risk of developing antiepileptic-induced severe cutaneous adverse reactions (SCARs). SCARs included Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS). Negative results were also seen when considering phenobarbital and phenytoin subgroups.	carbamazepine; phenobarbital; phenytoin
981859192	rs17183814	PMCID:PMC3125053	SCN2A	Allele A is associated with non-response when treated with carbamazepine, phenytoin or valproic acid in people with Epilepsy as compared to allele G.	yes	= 0.03	402		Central/South Asian	Efficacy	false	Authors note that association was found at the allele level but not at the genotype level, and that this may be due to a low number of AA individuals.	carbamazepine; phenytoin; valproic acid
1448266671	rs1045642	PMID:26421491	ABCB1	Allele A is not associated with concentrations of carbamazepine in people with Epilepsy as compared to allele G.	no	= 0.546			East Asian	Metabolism/PK	false		carbamazepine
1184746848	rs3094188	PMCID:PMC3173287	PSORS1C3	Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele C.	yes	= 2.93E-8	424	1881	Unknown	Toxicity	false	GWAS comparing cases with drug-induced Stevens Johnson Syndrome, Toxic Epidermal Necrolysis or both, with controls. Odds ratios were calculated for all drugs, and for allopurinol.	allopurinol; carbamazepine; phenytoin